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BACKROUND  
The over-production of reactive oxygen species (ROS) associated with the 
pathogenesis of several disorders such as diabetes mellitus (DM) and periodontal 
disease (PD) can contribute to injury of the host tissue, significant impairment to cell 
integrity and can cause oxidative damage to a large number of molecules such as 
carbohydrates, lipids and DNA. Because the oxidative stress is intrinsically related 
to the pathogenesis of type 2 diabetes, dyslipidemia and PD, and it lead to DNA 
damage. One of the most established methods for evaluating DNA damage is the 
micronucleus (MN) test. The ROS-mediated tissue destruction could be measured 
by the final product of lipid peroxidation (LPO), such as malondialdehyde (MDA). 
C-reactive protein (CRP) an acute-phase protein found in the blood, the levels of 
which rise in response to inflammation is linked closely to diabetes and periodontal 
infection.  
AIM OF THE STUDY 
The aim of the study was to evaluate the effect of non-surgical periodontal 
therapy on the micronuclei frequency, serum Malondialdehyde and serum Hs – CRP 
levels in chronic periodontitis patients with and without well controlled type 2 
diabetes mellitus and healthy controls. 
OBJECTIVES 
(i) To assess the micronucleus frequency (MNF), as a biomarker for DNA 
damage in peripheral blood, in chronic periodontitis patients, with and 
without well controlled type 2 diabetes mellitus and healthy controls. 
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(ii) To evaluate and compare free radical damage in the form of serum 
malondialdehyde (MDA) levels in chronic periodontitis patients, with and 
without well controlled type 2 diabetes mellitus and healthy controls. 
(iii) To assess the serum high sensitive C – Reactive protein level in chronic 
periodontitis patients, with and without well controlled type 2 diabetes 
mellitus and healthy controls. 
MATERIALS AND METHODS 
 This was an interventional study including a total of 83 participants (28 
chronic periodontitis with well controlled type DM, 27 chronic periodontitis and 28 
healthy controls) of which 75 patients completed the three months foloow-up 
protocol. Clinical parameters (PI, GI PPD and CAL) and laboratory parameters 
(RBS, total cholesterol, triglycerides, CBMN frequency, HbA1c (%), MDA, and Hs-
CRP) were recorded at baseline and three months following non-surgical periodontal 
therapy.  
RESULTS 
 In the present study at baseline all the periodontal parameters like PI, GI, 
PPD, and CAL were elevated in group 1 and group 2 than group 3. There was no 
statistical difference in PI, GI at baseline among three groups. In terms of mean PPD 
and mean CAL was more in DM group compared to CP group. In other words 
chronic periodontitis with well controlled type 2 DM had more periodontal 
breakdown than in patients with chronic periodontitis alone. This shows that DM 
has additional effect on periodontium. 3 months after SRP all the clinical parameters 
are reduced significantly in all the groups. Similarly laboratory parameters like RBS, 
total cholesterol, triglycerides, CBMN frequency, MDA, and Hs-CRP levels were 
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elevated in group 1 and group 2 than group 3. These values significantly declined 
three months after non-surgical periodontal therapy.  
CONCLUSION 
 Mean CBMN frequency, MDA, and Hs-CRP levels were elevated in 
individuals with chronic periodontitis and chronic periodontitis patients with well 
controlled type 2 diabetes mellitus. This study provides evidence that non-surgical 
periodontal therapy contributes to reduction in CBMN frequency, serum MDA, and 
serum Hs-CRP levels in these patients. Larger clinical trials are needed to confirm 
these findings. 
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Periodontitis is a term used to describe an inflammatory process, initiated by 
plaque biofilm, that leads to loss of periodontal attachment to the root surface and 
adjacent alveolar bone and which ultimately results in tooth loss. The gram-negative 
anaerobic or facultative bacteria within the subgingival biofilm are the primary 
etiologic agents but the majority of periodontal destruction occurs due to an 
inappropriate host response to this pathogens.
1
  
A diverse range of endogenous chemical mediators organize the host 
response and controls the inflammatory response. These chemical signals regulate 
the traffic of leukocytes and control the leukocyte response. The classic eicosanoids 
such as prostaglandins and leukotrienes exert a wide range of actions and play a key 
role in inflammation. The chemical mediators include lipid derived mediators, 
cytokines, chemokines, reactive oxygen species (ROS), reactive nitrogen species 
etc.
2
  
The initial host response is the release of reactive oxygen species (ROS) via 
the metabolic process of respiratory burst in the Polymorphonuclear leukocytes 
(PMNL’s), macrophages and monocytes. Excessive production of these ROS results 
in oxidative stress in the body. Reactive oxygen species (ROS) have a very short life 
(10
-6
-10
-9
 seconds), so it is not easy to detect its presence. The ROS-mediated tissue 
destruction could be measured by the final product of lipid peroxidation (LPO), such 
as Malondialdehyde (MDA).
1 
No longer can periodontal diseases be considered simple bacterial infections. 
Rather, they are complex diseases of multifactorial nature involving an intricate 
interplay between the subgingival microbiota, the host immune and inflammatory 
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responses, and environmental modifying factors.
3
 Thus, periodontal health must not 
be considered solely in the context of plaque/bacteria levels and control but must 
embrace a holistic consideration and evaluation of all factors responsible for the 
emergence of disease, as well as the restoration and maintenance of health.
4
  
The relevance of recognizing such important determinants of periodontal 
health and disease as controllable and uncontrollable predisposing and modifying 
factors cannot be underestimated, and their assessment for each patient is crucial to 
attaining and maintaining clinical periodontal health. Diabetes mellitus has, for 
many years, been recognized as an important risk factor for periodontal diseases and 
associated with significantly higher prevalence and severity of periodontitis.
5 
Diabetes mellitus (DM) is a metabolic disorder characterized by 
hyperglycemia and insufficiency of secretion or action of endogenous insulin and is 
an established risk factor for periodontitis
6
. There are two main types of diabetes (i) 
Type 1 diabetes mellitus and (ii) Type 2 diabetes mellitus. More recent data have 
confirmed a significant association between chronic hyperglycemia and a high 
prevalence of severe periodontitis
6, 7
. Furthermore, in many diabetic patients DM is 
undiagnosed, and the prevalence of these individuals is increasing. Hence, DM 
represents an enormous public health challenge and is by far the principal systemic 
disease affecting periodontitis in terms of extent of population affected.
8
 In addition, 
there is accumulating evidence that periodontal inflammation may itself contribute 
to the onset and persistence of hyperglycemia, in that inflammation is associated 
with poorer glycemic control in individuals with DM and may be associated with an 
increase in incident DM in longitudinal prospective studies.
9  
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A factor associated with complications of DM is the process of non-
enzymatic glycation of proteins, lipids and nucleic acids, with subsequent formation 
of advanced glycation end products (AGEs). One of the main consequences of this 
adverse action is the formation of oxidative stress.
10 ‘‘Oxidative stress’’ can be 
defined as any disturbance in the balance of antioxidants and pro-oxidants in favor 
of the later due to different factors such as aging, drug actions and toxicity, 
inflammation and/or addiction.
11 
Oxidative stress induces cellular damage and 
insulin resistance, and emerges as the major mechanisms for related co-morbidities. 
In addition, patients with type 2 diabetes present a deficient antioxidant defense 
compared to normal individuals. The increased production of the ROS has also been 
assigned to the glycation of proteins and/or auto-oxidation of glucose during the 
process of hyperglycaemia. Therefore, besides to the AGEs, the oxidative stress 
presents an important role in the pathogenesis and complications of DM.
10
 
DM is well recognized as a risk factor for periodontal disease. Diabetic 
individuals present an increased prevalence, severity and progression of 
periodontitis, when compared to non-diabetic individuals. Subjects with type 2 DM 
are 2.8 times more likely to have destructive periodontal disease and 4.2 times more 
likely to have significant alveolar bone loss compared to systemically healthy 
subjects. Periodontal disease was proposed to be the sixth complication of DM. 
The over-production of ROS associated with the pathogenesis of several 
disorders such as DM, dyslipidemia and periodontal disease, can contribute to injury 
of the host tissue, significant impairment to cell integrity and can cause oxidative 
damage to a large number of molecules such as carbohydrates, lipids and DNA. 
Because the oxidative stress is intrinsically related to the pathogenesis of type 2 
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diabetes, dyslipidemia and PD, and it lead to DNA damage. One of the most 
established methods for evaluating DNA damage is the micronucleus (MN) test.
12
  
Micronuclei (MN) and other nuclear anomalies such as nucleoplasmic 
bridges and nuclear buds are biomarkers of genotoxic events and chromosomal 
instability. These genome damage events can be measured simultaneously in the 
cytokinesis block micronucleus cytome (CBMN) assay. 
The MN test analyses is based on the identification of a secondary nucleus 
(MN), which is originated from acentric chromosome fragments, acentric chromatid 
fragments, or whole chromosomes that fail to be included in the daughter nuclei at 
the completion of telophase during mitosis because they did not attach properly with 
the spindle during the segregation process in anaphase. These displaced 
chromosomes or chromosome fragments are eventually enclosed by a nuclear 
membrane and except for their smaller size are morphologically similar to nuclei 
after conventional nuclear staining.
 
Previous studies suggested that periodontal 
treatment may be effective in maintaining systemic health by decreasing circulating 
ROS.
12
 
 
The hyperglycaemia associated to uncontrolled DM increases the formation 
of AGEs, including low density lipoprotein (LDL)-AGE, and is associated with the 
largest amount of LDL-oxidised. Both AGEs and LDL-oxidised, present at the same 
time in the blood of patients with DM, have several biological effects on 
lymphocytes and monocytes. These cells are involved in the pathogenesis of various 
diseases associated with DM, such as lower resistance to infections, vascular disease 
and greater severity of the periodontitis.
10 
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C-reactive protein (CRP) an acute-phase protein found in the blood, the 
levels of which rise in response to inflammation is linked closely to diabetes and 
periodontal infection. All studies on periodontitis patients with diabetes clearly 
demonstrate that the inflammatory response in such patients is related to increase in 
CRP.
13 
Recent investigations emphasized the role of moderate elevation of CRP 
levels as a risk factor for cardiovascular diseases.
14
 Studies suggested that non-
surgical periodontal therapy significantly suppress the serum C-reactive protein 
level in chronic periodontitis patients with type 2 diabetes mellitus.
15 
Elevated concentrations of a variety of oxidative stress markers were linked 
with a more frequent occurrence of cardiac events. High levels of micronuclei have 
been detected to be significantly correlated with Type 2 diabetes mellitus as well as 
with the occurrence and the severity of coronary artery disease (CAD). An elevated 
level of MDA indicates increase in production of oxygen free radicals suggesting the 
possible risk in atherogenesis, leading to coronary heart diseases
16
. There is strong 
evidence that inflammation plays a key role in the cascade of atherosclerosis, from 
its beginning to development of instability and plaque rupture. Raised levels of 
inflammatory mediators particularly CRP predict cardiovascular events. HsCRP is a 
powerful marker of vascular risk in a wide range of populations and, as such, is a 
powerful research tool in assessing at-risk populations. Determination of these 
markers contributes to understanding the development of and prevention of CVS 
disorders.
17
 All three bio markers include Micronuclei, Malondialdehyde, and 
HsCRP will be higher in patients with periodontitis, Type 2 diabetes mellius and 
cardiovascular diseases. Non-surgical periodontal therapy includes scaling and root 
planing will reduce the bacterial load thus reduce the amount of inflammation. 
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Various studies suggested that non-surgical periodontal therapy effectively reduce 
the levels of MDA and hs-CRP thus reducing the cardiovascular risk. Kanduluru et 
al 2014
18
 showed that nonsurgical periodontal treatment resulted in lower glycemic 
levels and the reduction of clinical parameters of periodontal infection, confirming 
the existing relation between type 2 DM and periodontal disease. Katagiri et al 
2009
15
 demonstrated that periodontal treatment with topical antibiotics was effective 
towards the improvement of glycemic control in type 2 diabetic patients with 
periodontal disease when associated with a decrease in serum hs-CRP. 
The present study designed to compare the micronuclei frequency in 
peripheral blood, serum Malondialdehyde level, and serum high sensitive C - 
reactive protein at baseline and 3 months after non-surgical periodontal therapy in 
chronic periodontitis patients with and without well controlled type 2 diabetes 
mellitus, and in patients with healthy periodontium. 
  
 
  
 
 
   
 
 
 
 
 
Aims & Objectives 
Aims & Objectives 
 
   Page 7 
 
Aim of the study  
The aim of the study was to evaluate the effect of non-surgical periodontal 
therapy on the micronuclei frequency, serum Malondialdehyde and serum Hs – CRP 
levels in chronic periodontitis patients with and without well controlled type 2 
diabetes mellitus and healthy controls. 
Objectives of the study 
(i) To assess the micronucleus frequency (MNF), as a biomarker for DNA 
damage in peripheral blood, in chronic periodontitis patients, with and 
without well controlled type 2 diabetes mellitus and healthy controls. 
(ii) To evaluate and compare free radical damage in the form of serum 
Malondialdehyde (MDA) levels in chronic periodontitis patients, with 
and without well controlled type 2 diabetes mellitus and healthy 
controls. 
(iii) To assess the serum high sensitive C – Reactive protein level in 
chronic periodontitis patients, with and without well controlled type 2 
diabetes mellitus and healthy controls. 
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Diabetes mellitus (DM) is a metabolic disorder characterized by 
hyperglycemia and insufficiency of secretion or action of endogenous insulin and is 
an established risk factor for periodontitis.
6
 There are two main types of diabetes (i) 
Type 1 diabetes mellitus and (ii) Type 2 diabetes mellitus. More recent data have 
confirmed a significant association between chronic hyperglycemia and a high 
prevalence of severe periodontitis.
6,7
 Furthermore, in many diabetic patients DM is 
undiagnosed, and the prevalence of these individuals is increasing. Hence, DM 
represents an enormous public health challenge and is by far the principal systemic 
disease affecting periodontitis in terms of extent of population affected.
8
 In addition, 
there is accumulating evidence that periodontal inflammation may itself contribute 
to the onset and persistence of hyperglycemia, in that inflammation is associated 
with poorer glycemic control in individuals with DM and may be associated with an 
increase in incident DM in longitudinal prospective studies.
9  
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Exacerbated and dysregulated inflammatory responses are at the heart of the 
proposed two-way interaction between diabetes and periodontitis, and the 
hyperglycaemic state results in various proinflammatory effects that impact on 
multiple body systems, including the periodontal tissues. Adipokines produced by 
adipose tissue include proinflammatory mediators such as TNF-α, IL-6 and leptin. 
The hyperglycaemic state results in deposition of AGEs in the periodontal tissues (as 
well as elsewhere in the body), and binding of the receptor for AGE (RAGE) results 
in local cytokine release and altered inflammatory responses. Neutrophil function is 
also altered in the diabetic state, resulting in enhancement of the respiratory burst 
and delayed apoptosis (leading to increased periodontal tissue destruction). Local 
production of cytokines in the periodontal tissues may, in turn, affect glycaemic 
control through systemic exposure and an impact on insulin signalling. All of these 
factors combine to contribute to dysregulated inflammatory responses that develop 
in the periodontal tissues in response to the chronic challenge by bacteria in the 
subgingival biofilm, and which are further exacerbated by smoking.
19 
 The hyperglycaemia associated to uncontrolled DM increases the 
formation of AGEs, including low density lipoprotein (LDL)-AGE, and is associated 
with the largest amount of LDL-oxidised. Both AGEs and LDL-oxidised, present at 
the same time in the blood of patients with DM, have several biological effects on 
lymphocytes and monocytes. These cells are involved in the pathogenesis of various 
diseases associated with DM, such as lower resistance to infections, vascular disease 
and greater severity of the periodontitis.
10 
Elevated concentrations of a variety of oxidative stress markers were linked 
with a more frequent occurrence of cardiac events. High levels of micronuclei have 
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been detected to be significantly correlated with Type 2 diabetes mellitus as well as 
with the occurrence and the severity of coronary artery disease (CAD). An elevated 
level of MDA indicates increase in production of oxygen free radicals suggesting the 
possible risk in atherogenesis, leading to coronary heart diseases.
16
 There is strong 
evidence that inflammation plays a key role in the cascade of atherosclerosis, from 
its beginning to development of instability and plaque rupture. Raised levels of 
inflammatory mediators particularly CRP predict cardiovascular events. HsCRP is a 
powerful marker of vascular risk in a wide range of populations and, as such, is a 
powerful research tool in assessing at-risk populations. Determination of these 
markers contributes to understanding the development of and prevention of CVS 
disorders.
17
 
MICRONUCLEI IN PERIODONTITIS AND DIABETES MELLITUS 
Periodontal tissue destruction and local inflammation were significantly 
more severe in diabetics. Frequency of binucleated cells with MN and MNF, as well 
as nucleoplasmic bridges, were significantly higher for poor controlled diabetics 
with dyslipidemia and PD in comparison with those systemically healthy, even after 
adjusting for age, and considering Bonferroni’s correction. Elevated frequency of 
micronuclei was found in patients affected by type 2 diabetes, dyslipidemia and PD. 
This result suggests that these three pathologies occurring simultaneously promote 
an additional role to produce DNA impairment. In addition, the micronuclei assay 
was useful as a biomarker for DNA damage in individuals with chronic degenerative 
diseases. 
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There is an increasing effort worldwide to determine the impact of 
environmental, genetic and life-style factors on genomic stability in human 
populations. One technique that has been adopted by numerous laboratories is the 
measurement of micronuclei (MN) in peripheral blood lymphocytes, epithelial cells, 
erythrocytes and fibroblasts.
20 
Srinivasan et al 2017 demonstrate cytologic changes of the exposed oral 
epitheial cells using H&E staining, concluded that micronuclei frequency, enlarged 
nucleus, perinuclear halo, binucleation, cytoplasmic streaks, candida and 
inflammation were found to be statistically significant.
21 
Rathod et al 2016 assess the micronucleus frequency (MNF), as a biomarker 
for DNA damage, in individuals with type 2 Diabetes Mellitus and chronic 
periodontitis. A total of 60 subjects were recruited for the study and divided into 
three groups. 20 subjects of group 1 had diabetes mellitus along with chronic 
periodontitis, Subjects with Diabetes mellitus and healthy periodontium were 
allotted to group 2 and group 3 include Subjects without Diabetes melilitus and with 
Chronic Periodontitis. Periodontal clinical examination was done. Blood sample 
collected was use to prepare a slide which was fixed in 5% giemsa solution and was 
analyzed in microscope then scoring of micronuclei was done. The mean 
micronuclei observed in group 1, 2 and 3 were 14.8, 11 and 10.85 respectively i.e. 
group 1 shows  significantly greater damage than other two groups. It was concluded 
that CBMN method was useful as a biomarker for DNA damage in individuals with 
chronic degenerative systemic diseases such as type 2 DM, as well as chronic local 
disease, such as PD.
12 
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Zamora Perez et al 2015 evaluate DNA and oxidative damage in subjects 
with chronic or aggressive periodontitis and healthy controls. Buccal mucosa cells 
and whole saliva were collected from 160 subjects, who were divided into three 
groups: subjects with chronic periodontitis (CP) (n = 58), subjects with aggressive 
periodontitis (AgP) (n = 42) and a control group (n = 60). DNA damage was 
determined by counting micronuclei (MN) and nuclear abnormalities (NAs) in 
exfoliated cells, including binucleated cells, cells with nuclear buds and karyolitic, 
karyorrhectic, condensed chromatin and pyknotic cells. The degree of oxidative 
stress was determined by quantifying 8-hydroxy-20-deoxyguanosine (8-OHdG) in 
whole saliva. Subjects with CP or AgP presented significantly more (p < 0.05) MN 
and NAs and higher levels of 8-OHdG (p < 0.05) compared with the control group. 
Their results indicate that subjects with periodontitis (CP or AgP) exhibited an 
increase in the frequency of MN, NAs and 8-OHdG, which is directly related to 
DNA damage. In addition, a positive correlation exists between oxidative stress 
produced by periodontitis disease and MN.
22 
Corbi et al 2014 assess the micronucleus frequency (MNF), as a biomarker 
for DNA damage, in individuals with type 2 DM, dyslipidemia and PD. One 
hundred and fifty patients were divided into five groups based upon diabetic, 
dyslipidemic and periodontal status (Group 1 – poor controlled DM with 
dyslipidemia and PD; Group 2 – well-controlled DM with dyslipidemia and PD; 
Group 3 – without DM with dyslipidemia and PD; Group 4 – without DM, without 
dyslipidemia and with PD; and Group 5 – without DM, dyslipidemia and PD). 
Blood analyses were carried out for fasting plasma glucose, HbA1c and lipid profile. 
Periodontal examinations were performed, and venous blood was collected and 
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processed for micronucleus (MN) assay. The frequency of micronuclei was 
evaluated by cell culture cytokinesis-block MN assay.
10 
Bastos-Aires et al 2013 characterize the frequency of micronuclei according 
to the periodontal status. For this purpose, we analysed oral exfoliated cells of 30 
patients matched by age and sex (15 control patients with healthy periodontum to 
mild periodontitis and 15 patients with moderate to severe periodontitis). Our results 
indicated a 2.3-fold increase in MN basal levels in patients with moderate to severe 
periodontitis compared to the control patients (P < 0.001), suggesting that the 
periodontal status may affect MN reference levels. Periodontal disease can cause 
changes in baseline levels of MNs. These preliminary results indicate that a better 
characterization of oral health factors, which might influence MN levels in oral 
epithelial cells.
23 
 Avula et al 2012 in their study Micronuclei frequency was analyzed 
in the peripheral lymphocytes of 10 patients with chronic periodontitis (CP), 10 
patients with generalized aggressive periodontitis (GAP) and 10 healthy controls. 
Various clinical parameters like the probing depth, clinical attachment level, and 
percentages of sites with bleeding and plaque were recorded. The results indicated 
that the cytogenetic damages in the periodontitis groups were not different from 
those in the control group.
24 
 Shettigar et al 2012 evaluated the induction of micronuclei due to 
increased glycosylation in type 2 diabetes. Forty-nine subjects divided into two 
groups of normoglycemic controls and type 2diabetic cases were recruited in the 
study. Whole blood was cultured and micronuclei were scored in all the cases. This 
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was correlated with age, sex, blood glucose levels and glycosylated hemoglobin. 
Age and sex matched diabetic patients had an increased micronuclei frequency in 
response to elevated glycosylation of haemoglobin compared to normoglycemic 
subjects. The increased glycosylation seems to induce oxidative damage in the DNA 
of the diabetic patients, which manifests as an increased micronuclei frequency. This 
has a potential to be used as a biomarker for subsequent diabetic complications.
25 
 Zuniga-Gonzalez et al 2007 demonstrated that either controlled 
(glycosylated haemoglobin levels 7%) or uncontrolled diabetic patients 
(glycosylated haemoglobin levels.7%) had 2-fold higher frequency of MNs in 
buccal mucosa samples than healthy subjects.
26 
 Martinez Perez et al 2007 A case–control study was carried out on a 
sample of 15 Mexican patients (40–56 years old) with type 2 diabetes mellitus 
(DM2) that had developed five years and been treated with oral hypoglycemic drugs 
(sulfonylurea and/or metformin), with no microvascular or macrovascular 
complications. Result showed a MN frequency significant increase in DM2 patients 
(6.53 ± 2.03 per 1000 cells) relative to that of the control group (3.10 ± 1.79 per 
1000 cells). MN may constitute a possible component of a panel of biomarkers for 
the risk of DM2.
27 
MDA IN PERIODONTITIS AND DM 
Periodontitis is a term used to describe an inflammatory process, initiated by 
plaque biofilm, that leads to loss of periodontal attachment to the root surface and 
adjacent alveolar bone and which ultimately results in tooth loss.
 
The gram-negative 
anaerobic or facultative bacteria within the subgingival biofilm are the primary 
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etiologic agents but the majority of periodontal destruction occurs due to an 
inappropriate host response to these pathogens.
 
Polymorphonuclear leukocytes 
(PMNs) are the primary mediators of host response against pathogens
 
and they 
generate increased levels of reactive oxygen species (ROS).
 
Reactive oxygen species 
(ROS) is a term collectively describing oxygen free radicals and other non-radical 
oxygen derivatives involved in oxygen radical production. Reactive oxygen species 
(ROS) have a very short life (10
-6
-10
-9 
seconds), so it is not easy to detect its 
presence. The ROS-mediated tissue destruction could be measured by the final 
product of lipid peroxidation (LPO), such as malondialdehyde (MDA). Oxidative 
stress is implicated in various pathological conditions such as rheumatoid arthritis, 
DM, and Periodontitis.
1 
Trivedi et al 2014 evaluate and compare free radical damage in the form of 
malondialdehyde (MDA) levels in whole saliva and plasma in diabetic chronic 
periodontitis patients and systemically healthy chronic periodontitis patients. Sixty 
CP patients (30 type 2 diabetics [DMCP] and 30 systemically healthy [CP]) and 60 
periodontally healthy (30 type 2 diabetics [DMPH] and 30 systemically healthy 
[PH]) were included in the study. After clinical measurements, blood and saliva 
samples were collected. SOD, GR, and CAT activities in red blood cell (RBC) lysate 
and saliva and MDA levels in plasma and saliva samples were 
spectrophotometrically assayed. ANOVA test followed by post-hoc test was used to 
compare the intra and inter group variances amongst the study groups. MDA levels 
in both the periodontitis groups were higher than periodontally healthy groups but 
the difference between CP and DMCP groups did not reach statistical significance 
(p>0.05). This study favors the role of oxidative stress in both diabetes and 
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periodontitis. It shows that the compensatory mechanism of the body is partially 
collapsed due to excessive production of free radicals during periodontitis, and is not 
able to cope with increased free radical generation due to diabetes thereby 
worsening the situation.
1 
A meta-analysis by Liu et al 2014 show that periodontitis patients had 
higher MDA levels than periodontal healthy controls (SMD = 0.99; 95% CI: 0.12, 
1.86; 𝑃 = 0.026). This meta-analysis systematically summarized the results of 16 
independent studies from different countries and suggested that oxidative stress 
biomarkers TAOC levels in peripheral blood were lower and MDA and NO levels in 
peripheral blood were higher in periodontitis patients than healthy subjects, which 
indicated an elevation in systemic oxidative stress status in periodontitis patients. 
This evidence suggested that chronic periodontitis was associated with systemic 
oxidative stress in human bodies. Our findings further indicated that clinical 
intervention of periodontitis may be beneficial for periodontitis patients systemic 
oxidative stress control and reduce its potential effect to systemic diseases.
28 
Al-Rawi et al 2011 assess the salivary content of lipid peroxidation and 
antioxidants in patients with type 2 diabetes. They studied 25 patients with type 2 
diabetes and other 25 age- and sex-matched health control. To evaluate the oxidative 
status we measured the levels of malondialdehyde (MDA) in the saliva and serum of 
all participants. Lipid profile was also estimated through measuring total cholesterol, 
triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C) and very low-density lipoprotein cholesterol (VLDL-C) levels. 
Antioxidant levels were also assessed through measuring the salivary and serum 
concentration of uric acid, superoxide dismutase and reduced glutathione (GSH). 
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The high concentration of lipid fractions in saliva usually follows that recorded in 
serum. Salivary MDA levels, a product of lipid peroxidation, were significantly 
increased among diabetics together with uric acid. However, GSH levels were 
similar to those of the control group. In this study concluded that Lipid peroxidation 
and antioxidant parameters assessed in saliva of diabetic patients may be of great 
importance in evaluating the disease activity and severity. The increase in lipid 
peroxidation and the tendency of antioxidants to rise in diabetes is probably due to 
an adaptive response to the pro-oxidant status of diabetes.
29 
Akalin et al 2007 investigated MDA levels and total oxidant status (TOS) in 
serum, saliva and gingival crevicular fluid (GCF) in patients with chronic 
periodontitis (CP). Thirty-six CP patients and 28 periodontally healthy controls were 
included in the study. Following clinical measurements and samplings, MDA and 
TOS levels were measured by high-performance liquid chromatography and a novel 
automatic colorimetric method, respectively. While the saliva and GCF MDA levels 
and serum, saliva and GCF TOS values were significantly higher in the CP group 
than the control group, no significant difference in serum MDA levels was found. 
Strong positive correlations were observed between periodontal parameters and 
MDA and TOS levels. The results revealed that LPO significantly increased locally 
in the periodontal pocket/oral environment, while TOS displayed both systemic and 
local increases in periodontitis. The findings suggest that increased LPO and TOS 
may play an important role in the pathology of periodontitis, and are closely related 
to the clinical periodontal status.
30 
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Hs-CRP IN PERIODONTITIS AND DM 
 The role of periodontal disease in the etiology of cardiovascular 
disease (CVD) has recently received considerable attention. Several observational 
epidemiologic studies have found that poor periodontal health status is associated 
with an increased risk for CVD.
31 
C-reactive protein an acute-phase protein found in the blood, the levels of 
which rise in response to inflammation is linked closely to diabetes and periodontal 
infection. In various diseases that result in tissue injury or inflammation, the CRP 
levels may rise within hours after an acute event. It is though that elevated CRP 
levels assist in complement binding to foreign and damaged cells and enhance the 
humoral response to the disease. 
 The function of immune cells including neutrophils is decreased in 
diabetes but the monocyte/macrophage cell line may be hyper responding when 
faced with bacterial antigenic contact. This hyper response results in a greater 
production of pro-inflammatory cytokines as tumor necrosis factor alpha and IL-6, 
which result in elevation of CRP levels. The measurement of elevated CRP levels in 
periodontitis and diabetes are helpful in clinical diagnosis, therapy and monitoring 
of inflammatory conditions.
13 
Gupta et al 2017 assessed the levels of CRP in patients with and without 
periodontitis and their relation with BMI and smoking behaviour. Total 31 subjects 
in each group: Case (periodontitis) and Control (without periodontitis) were selected 
using convenience sampling technique. All subjects underwent periodontal 
examination by a single examiner. Serum CRP samples were taken before 
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periodontal treatment. Results showed increase in mean CRP levels in periodontitis 
(5.8595mg/L) with high statistical significance (P=0.000) in comparison to subjects 
without periodontitis (1.1214mg/L) was observed. BMI showed positive association 
with periodontitis (P=0.046) but not with CRP (0.213). Smoking behaviour showed 
no significant relation with either CRP (P=0.344) or periodontitis (P=0.541). They 
found highly significant association between periodontitis and CRP levels but not 
always with BMI and smoking. CRP, which is an established marker for CVD was 
significantly increased in periodontal infections. Hence, a close interaction among 
Physician, Periodontist and Patient to prevent adverse health situations is 
recommended.
32 
Martu et al 2017 investigated the serum C-reactive protein (CRP) values in 
the presence of A.actinomycetemcomitans, P. gingivalis, T. denticola or T. forsythia 
bacteria, as an indicator of the cardiovascular risk. The study consisted of 64 male 
and female subjects, aged 55 to 75 years. Periodontal parameters were examined, 
serum CRP was analyzed, and Porphyromonas gingivalis, A. 
actinomycetemcomitans, T. forsythia and T. denticola from the subgingival bacterial 
plaque were detected by real-time quantitative polymerase chain reaction (qPCR). 
Pathogen prevalence rates were: 45.0% P. gingivalis; 20.5% A. 
actinomycetemcomitans; 86.1% T. forsythia; 86.3% T. denticola. The mean CRP 
was 1.5 mg / L. There was a significant difference in CRP values between subjects 
who had P. gingivalis compared to those without. There were no significant 
differences for any of the other pathogens. The presence of P. gingivalis was 
associated with a 1.20-fold increase in CRP. Of the four periodontal pathogens 
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investigated, only the presence of P. gingivalis in subgingival plaque samples was 
significantly associated with a high level of C-reactive protein.
33 
Anwar et al 2016 examined the plasma C-reactive protein levels in Pakistani 
population in association with periodontitis and diabetes. Patients were divided in 
four groups; group I (normal healthy), group 2 (periodontitis), group 3 (diabetes) 
and group 4 (both periodontitis and diabetes). Each group comprised 20 patients. 
Patients who have at least 15 teeth and age between 30-60 years were included. The 
obtained values of the patient samples and control sera were multiplied by dilution 
factor of 100 to obtain CRP results in mg/l. Statistically significant difference of C-
reactive protein levels is present between periodontitis, diabetes and periodontitis 
diabetes group as compared to control group (P<0.05). They concluded that the CRP 
levels are raised with periodontitis and diabetes, and if both are present in a person, 
these levels are further elevated.
13 
Shojaee et al 2013 compared of the amount of salivary C - reactive protein 
(CRP) in healthy subjects and patients with periodontal disease. In this study 
subjects were divided into three groups of healthy (n = 30), gingivitis (n = 30), and 
chronic periodontitis (n = 30), based on Gingival Index (GI) and Clinical 
Attachment Loss (CAL) indices. 2ml saliva samples were collected from these 
people and clinical indicators including GI, CAL, Periodontal Pocket Depth (PPD), 
and Bleeding Index (BI) were assessed. ELISA method was used to evaluate the 
salivary CRP levels. The statistical analysis showed a significant difference in 
salivary CRP concentrations between the periodontitis patients and healthy subjects. 
The results indicate that there is a significant association between periodontitis and 
salivary CRP concentrations.
34 
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Nakajima et al 2010 found out that the concentrations of hs-CRP and IL-6 
in the sera of periodontitis patients was significantly higher than those in control 
subjects. They concluded that Although periodontal infection does affect the 
concentration of hs-CRP and IL-6 in serum, a subgroup of patients exist who are 
highly susceptible to an increased risk of CHD associated with periodontitis, 
suggesting that there may be subjects who have an elevated risk of CHD 
independent of susceptibility to periodontal tissue destruction per se.
35 
A systematic review and meta-analysis by Paraskevas et al 2008 explored 
the robustness of observations that CRP is elevated in periodontitis. Similarly, the 
effect of periodontal therapy on CRP levels was investigated. In conclusion, this 
systematic review provides evidence that periodontitis elicits a mild acute-phase 
response with elevation of CRP levels compared with healthy controls. Periodontal 
treatment results in lowered CRP levels.
36 
Salzberg et al 2006 were working on elevated levels of C-reaction protein in 
periodontitis. The elevated inflammatory cytokines levels associated with 
destructive periodontal diseases cause an increase in CRP levels.
37 
Persson et al 2005 assess periodontal status and hsC-rp serum levels in 
consecutive subjects hospitalized and diagnosed with acute myocardial infarction 
(AMI) and in a group of carefully matched subjects (gender, age social, ethnic, and 
smoking habits) without clinical evidence of CVD. They found that the hs-CRP 
level to be above 10.0 mg/l in all the subjects in which evidence of significant 
alveolar bone loss was present indicating periodontitis. Thus, the level of CRP tends 
to increase with the periodontal destruction marked by ABL.
38 
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Joshipura et al 2004 evaluated cross-sectionally the association between 
periodontal disease and C-reactive protein (CRP), fibrinogen, factor VII, tissue 
plasminogen activator (t-PA), LDL-C, von-Willebrand factor, and soluble tumor 
necrosis factor receptors 1 and 2. They concluded that periodontal disease showed 
significant associations with biomarkers of endothelial dysfunction and 
dyslipidemia, which may potentially mediate the association between periodontal 
and cardiovascular disease.
39 
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STUDY DESIGN 
 This is a comparative interventional study for evaluating the 
Micronuclei frequency, serum Malondialdehyde levels and serum High sensitive C-
reactive protein levels in chronic periodontitis patients with and without well 
controlled type 2 diabetes mellitus before and 3 months after scaling and root 
planning procedures.  
STUDY SETTING 
 Chronic periodontitis patients with and without diabetes mellitus 
patients for the study were selected from the outpatient of department of 
periodontics, Sree mookambika institute of dental sciences, Kulasekaram. 
STUDY DURATION 
 The study duration was of one year, which lasted from January 2018 
to December 2018. 
INFORMED CONSENT AND ETHICAL CONSIDERATIONS 
 The study protocol was approved by the institutional research 
committee of Sree mookambika institute of dental sciences (Ref No: 17/09/2017) 
and also by the Institutional Human Ethics Committee of Sree mookambika institute 
of medical sciences, Kulasekaram (SMIMS/IHEC No: 2/PROTOCOL No: 36/2017) 
and was registered under the Clinical trials Registry of India 
(CTRI/2018/09/015803). 
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Study protocol was explained to patient and the information on the nature 
and potential benefit of their participation in the study was also explained. Informed 
consent was obtained from all subjects after screening. 
SAMPLE SIZE CALCULATION 
Sample size was calculated based on the previous study by Rathod et al 
2016. 
The sample size N= 
  
  
(     )  
       
       
        
   = 0.84 
       
       
Power = 1-  = 80% 
N= 
  
  
(     )  = 15.7x 
     
 
  = 21.8 rounded off to 25 for each group. 
The number of participants required in each intervention group is 25. 
Total sample size = 3x25 = 75 
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The selected patients were assigned into three groups, each group consisting 
of 25 patients 
Group I – Twenty five chronic periodontitis patients with well controlled 
type 2 diabetes mellitus. 
Group II – Twenty five chronic periodontitis without type 2 diabetes mellitus 
Group  III – Twenty five healthy control patients 
INCLUSION CRITERIA 
Group I – Twenty five chronic periodontitis patients with well controlled 
type 2 diabetes mellitus. 
1. Patients with chronic periodontitis was diagnosed when there was 
two or more interproximal sites with CAL > 4 mm, not on the same 
tooth, or two or more interproximal sites with PPD > 5 mm, not on 
the same tooth. (Page and Eke 2007) 
2. Patients with > 20 teeth 
3. Patients with clinical bleeding on probing 
4. Patients were considered to be well controlled Type 2 diabetic when 
presenting with fasting blood glucose levels of 126mg/dL, and 
glycated hemoglobin (6.0 to 6.5%). [According to the criteria of 
American Diabetes Association 2010] 
Group II – Twenty five chronic periodontitis without type 2 diabetes mellitus 
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1. Patients with chronic periodontitis was diagnosed when there was 
two or more interproximal sites with CAL > 4 mm, not on the same 
tooth, or two or more interproximal sites with PPD > 5 mm, not on 
the same tooth. (Page and Eke 2007) 
2. Patients with > 20 teeth 
3. Patients with clinical bleeding on probing 
Group  III – Twenty five healthy control patients 
1. Patients with clinical bleeding on probing 
2. Patients with > 20 teeth 
EXCLUSION CRITERIA 
Subjects will be excluded if 
1) They suffer from any systemic condition (except Type 2 Diabetes mellitus) 
that could affect the progression of periodontal disease (immunological 
disorders), smokers and former smokers, alcoholics and former alcoholics, 
obese, pregnant and lactating women and those taking oral contraceptive 
drugs. 
2) There is a presence of an active infection other than periodontitis. 
3) There is an intake of antibiotics/ corticosteroids and or non-steroidal anti-
inflammatory drugs during the previous 4 weeks. 
4) Any previous history of benign or malignant tumours. 
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5) They had received professional periodontal treatment during the 6 month 
period prior to the study. 
6) They had used mouth rinses containing antimicrobials in the preceding 2 
months. 
7) Subjects with periapical pathology, orthodontic appliances and multiple 
systemic complications of diabetes mellitus, inflammatory bowel disease, 
psoriasis, RA, Nephritis will also be excluded from the study. 
CLINICAL PARAMETERS 
 Periodontal examination was conducted in the Department of 
Periodontics, Sree Mookambika institute of dental sciences, Kulasekaram. The 
following clinical parameters were assessed using UNC 15 probe (Colour Plate – 
1). Clinical parameters were measured at six sites of all teeth (mesiobuccal, 
miduccal, distobuccal, mid lingual and distolingual) at baseline and 3 months 
following non-surgical periodontal therapy. 
1. Plaque index(PI) 
2. Gingival index (GI) 
3. Probing pocket depth (PPD) 
4. Clinical attachment level (CAL) 
LABORATORY PARAMETERS 
1. Micronuclei frequency (MN) 
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2. Serum Malondialdehyde (MDA) level 
3. Serum High sensitive C-reactive protein level (Hs-CRP) 
4. Glycated haemoglobin (HbA1C) 
5. Random blood sugar (RBS) 
6. Total cholesterol level 
7. Triglycerides 
ARMAMENTARIUM 
 The collection of blood and non-surgical periodontal therapy were 
performed with the following equipment’s (Colour Plate – 2) 
1. Mouth mirror 
2. UNC 15 periodontal probe 
3. Gracey area specific curette 
4. 23 Gauge 6 ml disposable syringe 
5. Clot activator tube 
6. Vacutainer  
7. REMI Laboratory centrifuge 
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PROCEDURE 
After the patients were included in the study, the 6 ml of blood was collected 
by venepuncture (Colour Plate – 3). PI, GI, PPD, and CAL were recorded from 
each patient of the three groups. The clinical and laboratory parameters recorded at 
baseline were given as T0. After baseline evaluation all the patients received non-
surgical periodontal therapy, which include oral hygiene instructions, supragingival 
and subgingival scaling and root planing under local anaesthesia using ultrasonic 
instruments and hand instruments as needed. Patients were recalled after 3 months 
during which clinical parameters were recorded  
SAMPLE PREPARAION  
Collect fresh blood by venepuncture and 3 ml of blood was transferred to 
heparinised vacutainers and remaining 3 ml blood was transferred into clot activator 
tube (Colour Plate – 4). This clot activator tube was centrifuged at 3000 rpm for 3 
minutes to separate serum (Colour Plate – 5, 6). Collected serum was transferred 
into ependorf tube. All the samples send on the same day to Genetika centre for 
advanced genetic studies, Pettah, Thiruvananthapuram, kerala. 
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PATIENTS WITH CHRONIC 
PERIODONTITIS, TYPE 2 DIABETES 
MELLITUS 
 
HEALTHY CONTROLS PATIENTS WITH CHRONIC 
PERIODONTITIS 
 
Blood Sample Taken 
 
PERIODONTAL PARAMETERS 
Plaque Index (Silness  and Loe , 
1964) 
Gingival Index (Loe and Silness, 
1963) 
Probing pocket depth  
Clinical Attachment Level (CAL) 
LAB PARAMETERS 
Micronuclei frequency 
Malondialdehyde level 
Hs – CRP level 
HbA1C level 
RBS 
Total cholesterol 
Triglyerides  
 
SCALING AND ROOT PLANING DONE 
 
AFTER THREE MONTHS 
 
LAB PARAMETERS 
Micronuclei frequency 
Malondialdehyde level 
Hs – CRP level 
HbA1C level 
RBS 
Total cholesterol 
Triglycerides  
 
PERIODONTAL PARAMETERS 
Plaque Index (Silness  and Loe , 
1964) 
Gingival Index (Loe and Silness, 
1963) 
Probing pocket depth  
Clinical Attachment Level (CAL) 
Patients coming to the Department of Periodontics 
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Protocol for CBMN assay 
Collect fresh blood by venepuncture and transfer to heparinised vacutainers 
and the collected blood samples are send on the same day to Genetika centre for 
advanced genetic studies, Trivandrum. 
1. Isolate lymphocytes on lymphoprep (pharmacia) gradients as follows: Add 
2ml of lymphoprep to a 10ml centrifuge tube and carefully overlay 4ml of 
diluted blood sample (Colour Plate – 8). 
2. Centrifuge at 1000rpm for 10min. 
3. Drawn off the lymphocyte layer using a sterile Pasteur pipette and transfer to 
a 10ml tube. 
4. Suspend the cell pellet in RPMI 1640 medium and centrifuge for 10 minutes. 
5. Remove the supernatant and repeat step 5. 
6. Culture the lymphocytes in sterile bottles using RPMI 1640 medium 
containing 15% foetal calf serum. Lymphocytes stimulate to divide with 
phytohaemagglutinin (PHA) and incubate for 72 hours at 37ºC (Colour 
Plate – 9). 
7. 44 hr after PHA stimulation, add cytochalasin-B to the cultures to give a 
final concentration of 4.5µg/ml (Colour Plate – 10). 
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8. 28 hr after addition of cytochalasin –B, transfer the whole contents into a 
sterile centrifuge tube and centrifuge for 10 minutes; remove the supernatant, 
shack the pellet in a cyclomixer. 
9. Add 10 ml of 0.075 M KCL solution to the cell button and kept at 37ºC for 
10 minutes (Colour Plate – 11). 
10. After this, add 2 drops of freshly prepared fixative (Methanol: Acetic acid) in 
the ratio 3:1.Again centrifuge at 1000 rpm for 10 minutes. 
11. Remove the supernatant and mix the cell button in a cyclomixer and add 10 
ml of freshly prepared fixative and centrifuge at 1000 rpm for 10 minutes. 
12. Repeat this process until the supernatant becomes clear and the cell button 
becomes white. 
13. From the cell button, prepare cell suspension. 
14. Drop the cell suspension drop by drop on to pre cleaned, labeled, and chilled 
slides (Colour Plate – 12). 
15. Air-dry the slides for 10 min, then fix in absolute methanol for 10 min and 
stain with May-Grunwald Giemsa for 10 minutes. 
16. Code the slides before scoring and examine at 100X magnification (Colour 
Plate – 13). The number of MN in no less than 1000 binucleated cells should 
be scored and the distribution of MN among binucleated cells should be 
recorded (Colour Plate – 14). 
Materials and Methods 
 
   Page 33 
 
CRITERIA FOR IDENTIFYING BINUCLEATED CYTOKINESIS BLOCK 
CELLS 
The cytokinesis blocked cells scored for micronucleus frequency have to 
satisfy the following criteria: 
 Cells should have two nuclei of approximately equal size; 
 The 2 nuclei may be attached by a fine nucleoplasmic bridge; and 
 The 2 nuclei may overlap slightly or touch each other at the edges. 
 Cells should not contain more than 6 micronuclei. 
CRITERIA FOR IDENTIFYING MICRONUCLEI 
Micronuclei are morphologically identical to, but smaller than normal nuclei. 
They also have the following characteristics. 
 Diameter between 1/6 and 1/3 that of the main nuclei. 
 They are non-refractile. 
 They are not linked to the main nuclei via a nucleoplasmic bridge. 
 Micronuclei may sometimes overlap the boundaries of the main nuclei. 
PREPARATION OF REAGENTS 
Phytohaemagglutinin (PHA-M: 5mg stock):- 
Dissolve 5mg stock of PHA-M in 5ml of distilled water. 
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Hypotonic KCl solution (0.075M):- 
Dissolve 5.6gm of KCl (99.9%), (MW-74.55) in 1000ml of distilled water. 
Fixative [Methanol and Glacial Acetic acid in the ratio 3:1 (v/v)]:- 
Mix three parts of absolute methanol (99.8%) (32.04g/mol) and one part of 
glacial acetic acid (99.7%) (MW-60.05). Methanol acts as a fixative and acetic acid 
as the scavenger. Better morphological fixation occurs at low temperatures. 
Cytochalasin-B: - Dissolve 1mg Cytochalasin-B in 1ml of dimethyl 
sulpoxide and store in freezer. 
PREPARATION OF MEDIA 
1) RPMI 1640 medium 
1. Suspend the content of one unit vial in 950 ml of sterililized tissue culture 
grade water at room temperature with constant, gentle stirring until the 
medium is completely dissolved. Rinse the container with tissue culture 
grade water to remove all traces of powder and add to the above solution. Do 
not heat the water. 
2. Add the required amount of sodium bicarbonate (2.25gm/l) as per the 
requirement and stir until dissolved. 
3. Adjust the pH to 0.2-0.3 pH unit below the desired pH (7.4) using 1N 
Hydrochloric acid or Sodium Hydroxide since the pH tends to rise during the 
filtration. 
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4. Aseptically add sterile supplements (100μgm/ml Benzyl penicillin, 
100units/ml streptomycin, 50μgm/ml Amphoterecin B, 15% foetal bovine 
serum, etc). Make up the final volume to 1000 ml with tissue culture grade 
water. 
5. Sterilize the medium immediately by filtering through a sterile membrane 
filter with porosity of 0.2 micron or less using positive pressure to minimize 
the loss of carbon dioxide and dispensed the desired amount of sterile 
medium in to sterile containers. Store at 2-6°C till use.  
Malondialdehyde (MDA) Malondialdehyde in serum is separated and determined 
as conjugate with Thiobarbituric acid (TBA). Serum proteins were precipitated by 
Trichloroacetic acid (TCA) and then removed by centrifugation. The MDA – TBA 
complex was measured at 540 nm
11
. 
Reagents 
 Reagent A- 15% TCA in 100ml 0.25N Hydrochloric acid 
 Reagent B- 0.375% TBA in 100ml 0.25N Hydrochloric acid 
 Mix reagent A & B well and keep it in 2-8 ºC. 
Protocol 
1. Collect venous blood and transferred to a free tube, then allow clotting. 
2. Centrifuged at 3000 rpm for 5 minutes & the serum are then removed to 
another plain tube & store at -2 ºC until the time of analysis.  
3. Add 1ml of serum into 2ml of reagent (TCA+TBA+HCl). 
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4. The tubes were mixed well & incubated in boiling bath for 15 minutes. 
5. Allow cooling, and then the tubes are left to stand at room temperature for 20 
minutes. 
6. Centrifuge at 2000 rpm for 15 minutes & then the supernatant layer was read 
at 540 nm (Colour Plate – 7). 
The concentration of MDA (nmol/ml) was calculated by using the following 
formula:  
  Concentration of the test   =    
   (    )   
    
 
  Reference range = 0.7 – 1.9 U/l 
High sensitive C Reactive Proteins or hs-CRP (Turbidometric Immunoassay)  
Principle: The hs-CRP is a turbidmetric immunoassay for ultrasensitive 
determination of C-reactive protein in human serum. It is based on the principle of 
agglutination reaction. The test specimen is mixed with latex reagent and activation 
buffer and allowed to react (Colour Plate – 15). The presence of CRP in the test 
specimen results in the formation of insoluble complex producing turbidity, which is 
measured at a wavelength between 505-578 nm. The increase in turbidity 
corresponds to the concentration of CRP in the test specimen
17, 18 
(Colour Plate – 
16). 
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Colour plate 1 – Recording clinical parameters 
 
Colour plate 2 – Armamentarium for non-surgical periodontal therapy 
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Colour plate 3 – Blood collection 
 
Colour plate 4 – Vacutainer (BD) and Clot activator tube 
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Colour plate 5 – REMI Laboratory centrifuge 
 
Colour plate 6 – Serum separation 
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Colour plate 7 – Semi auto analyser (MISPA – NEO) for MDA evaluation 
 
Colour plate 8 – Laminar air flow chamber 
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Colour plate 9 – Reagents for CBMN assay – RPMI-1640 (SIGMA), Cytochalasin 
B (SIGMA) and Phytohemagglutinin – M (BI) 
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Colour plate 10 – Cell culturing 
 
Colour plate 11 – Microbiological incubator (LABLINE) 
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Colour plate 12 – Cell harvesting 
 
Colour plate 13 – Laboratory microscope (OLYMPUS CX31) 
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Colour plate 14 – Cytokinesis-block binucleated cells with Micronuclei 
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Colour plate 15 – Hs-CRP kit (EURO DIAGNOSTIC SYSTEMS) 
 
 
Colour plate 16 – Semi auto analyser for Hs-CRP detection 
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STATISTICAL ANALYSIS 
 In this study we had three groups and parameters studied were PI, GI, PPD, 
CAL, Mean CBMN frequency, Serum MDA level, Serum Hs-CRP level, HbA1C, 
RBS, Total cholesterol and Triglycerides. The data was analysed by SPSS software 
(version 22.0). For describing these data we used percentage, mean value, SD, 
median depending on the variable type. Comparison between three group’s chronic 
periodontitis patients with well controlled type 2 DM, Chronic periodontitis patients, 
and healthy controls were done by using Chi square test, Parametric one way 
ANOVA and non-parametric one way ANOVA, whichever is appropriate. The 
results were presented in five different headings, 
1. Baseline Demographic, Metabolic, Periodontal and Laboratory data of 
the participants [Mean (SD)] 
2. Three Months Post-Operative Metabolic, and Periodontal data of the 
participants [Mean (SD)] 
3. Changes in Probing Pocket Depth and Clinical Attachment Level at 
Baseline and after 3 Months (%) 
4. Comparison of Periodontal and Laboratory data at baseline and 3 months 
after treatment [Mean (SD)] 
5. Differences in Metabolic, and Periodontal data of the participants at 
baseline and after 3 months [Mean (SD)] 
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RESULTS AND OBSERVATIONS 
TABLE 1: Baseline Demographic, Metabolic, Periodontal and Laboratory data 
of the participants [Mean (SD)] 
PARAMETERS GROUP 1 GROUP 2 GROUP 3 P VALUE 
AGE (YEARS) 48.425 + 6.9 36.926 + 5.5 32.7 + 2.5 0.000 
GENDER M/F 22/6 22/5 22/6 0.954 
PLAQUE INDEX 
(PI) 
1.6 + 0.22  1.61 + 0.25 1.32 + 0.18 0.00 
GINGIVAL 
INDEX (GI) 
1.8 + 0.26 1.74 + 0.32 1.31 + 0.28 0.00 
MEAN PPD (mm) 4.49 + 0.37 3.86 + 0.26 2.5 + 0.20 0.00 
MEAN CAL (mm) 4.80 + 0.37 4.29 + 0.41 2.5 + 0.20 0.00 
RBS (mg/dl) 146.6 + 22.7 94.29 + 8.2 90.3 + 12.3 0.00 
CBMN 
FREQUENCY 
(out of 1000 bi-
nucleated cells) 
13.20 + 0.53 12.11 + 0.43 9.84 + 0.49 0.00 
MDA LEVELS 
(U/L) 
3.41 + 0.29 2.73 + 0.47 1.14 + 0.33 0.00 
Hs-CRP(mg/L) 8.77 + 0.54 6.9 + 0.51 1.21 + 0.33 0.00 
HbA1C (%) 6.48 + 0.33 4.8 + 0.56 3.5 + 0.36 0.00 
TOTAL 
CHOLESTEROL 
(mg/dl)  
240.4 + 22.1 167.4 + 24.4 153.3 + 25.7 0.00 
TRIGLYCERIDES 
(mg/dl) 
256.3 + 57.41 114.1 + 23.01 112.9 + 13.5 0.00 
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Total of 83 participants were selected for this study of which 75 participants 
completed the study. Baseline demographic, metabolic, Periodontal and laboratory 
data are shown in Table 1. Twenty eight Chronic periodontitis patients with well 
controlled type 2 DM (Mean age 48.4 + 6.9), Twenty seven Chronic periodontitis 
patients (Mean age 36.926 + 5.5) and Twenty eight Healthy controls (Mean age 32.7 
+ 2.5) were enrolled in this study. All of the clinical as well as the laboratory 
parameters were significantly higher in the group 1 and group 2 compared to group 
3 at baseline. 
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TABLE 2: Three Months Post-Operative Metabolic, and Periodontal data of 
the participants [Mean (SD)] 
PARAMETERS GROUP 1 GROUP 2 GROUP 3 P VALUE 
PLAQUE INDEX 
(PI) 
0.34 + 0.13  0.32 + 0.14 0.27 + 0.06 0.13 
GINGIVAL 
INDEX (GI) 
0.41 + 0.19 0.41 + 0.19 0.36 + 0.39 0.017 
MEAN PPD (mm) 2.59 + 0.29 2.4 + 0.19 2.5 + 0.19 0.18 
MEAN CAL (mm) 2.97 + 0.30  2.76 + 0.20 2.5 + 0.19 0.00 
RBS (mg/dl) 131.3 + 20.4  91.12 + 9.44 87.2 + 9.4 0.00 
CBMN 
FREQUENCY 
(out of 1000 bi-
nucleated cells) 
12.80 + 0.46 11.87 + 0.50 9.6 + 0.45 0.00 
MDA LEVELS 
(U/L) 
2.5 + 0.58 2.35 + 0.49 1.01 + 0.26 0.00 
Hs-CRP(mg/L) 5.8 + 1.32 4.2 + 1.08  1.13 + 0.31 0.00 
HbA1C (%) 6.07 + 0.30 4.65 + 0.52 3.50 + 0.33 0.00 
TOTAL 
CHOLESTEROL 
(mg/dl)  
210.6 + 28.3 167.4 + 20.4 145.1 + 24.6 0.00 
TRIGLYCERIDES 
(mg/dl) 
225.08 + 
45.94 
111.7 + 20.7 108.2 + 13.9 0.00 
  
 Table 2 shows the changes in the periodontal parameters after three months 
of non-surgical periodontal therapy. PI, GI, mean PPD shows no statistical 
difference (p Value >0.05) in between groups at 3 months post operatively. All other 
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parameters like Mean CAL, RBS, Mean CBMN frequency, MDA, Hs-CRP, Total 
cholesterol, Triglycerides, and HbA1C values are statistically significant in between 
3 groups. (p Value <0.05) 
Table 3: Changes in Probing Pocket Depth and Clinical Attachment Level at 
Baseline and after 3 Months (%) 
PARAMETERS GROUP 1 
BASELINE    
POST OP 
GROUP 2 
BASELINE    
POST OP 
GROUP 3 
BASELINE    
POST OP 
PPD <3mm (%) 50.5 92.29 56.5 97.6 92.08 96.60 
PPD 4-6 mm (%) 42.35 6.27 40.5 2.35 7.9 3.39 
PPD > 7 mm (%) 7.1 1.42 2.94 0.0 0.0 0.0 
CAL <3mm (%) 51.68 87.13 52.70 95.41 91.16 95.3 
CAL 4-6 mm (%) 39.45 8.78 41.42 4.14 8.83 4.62 
CAL > 7 mm (%) 8.86 4.08 5.86 0.43 0.0 0.0 
 
Table 3 given are changes in PPD (%), CAL (%) at baseline and after 3 months. The 
percentage of shallow sites (PPD <3mm) increased significantly in all the groups but 
more so in group 1 and group 2 than group 3, whereas the percentage of sites with 
PPD of 4-6mm and > 7 mm decreased significantly in group 1 and 2 but more 
reduction occurred in group 2 than group 1. Similarly CAL % of shallow sites 
(<3mm) increased significantly in all the groups but more so in group 1 and group 2 
than group 3, whereas the percentage of sites with CAL of 4-6mm and > 7 mm 
decreased significantly in group 1 and 2 but more reduction occurred in group 2 than 
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group 1 suggesting that more clinical attachment gain occurred in group 2 than 
group 1. 
TABLE 4: Comparison of Periodontal and Laboratory data at baseline and 3 
months after treatment [Mean (SD)] 
PARAMETERS GROUP 1
  
GROUP 2 GROUP 3 P VALUE 
Mean PI Score Baseline  1.6 + 0.22 1.61 + 0.25 1.32 + 0.18 0.00 
Post op 0.34 + 0.13 0.32 + 0.14 0.27 + 0.06 0.13 
 p Value 0.00 0.00 0.00  
Mean GI score Baseline 1.8 + 0.26 1.74 + 0.32 1.31 + 0.28 0.00 
Post op 0.41 + 0.19 0.41 + 0.19 0.36 + 0.39 0.017 
 p Value 0.00 0.00 0.00  
Mean PPD 
(mm) 
Baseline 4.49 + 0.37 3.86 + 0.26 2.5 + 0.20 0.00 
Post op 2.59 + 0.29 2.4 + 0.19 2.5 + 0.19 0.18 
 p Value 0.00 0.00 0.53  
Mean CAL 
(mm) 
Baseline 4.80 + 0.37 4.29 + 0.41 2.5 + 0.20 0.00 
Post op 2.97 + 0.30 2.76 + 0.20 2.5 + 0.19 0.00 
 p Value 0.00 0.00 0.662  
RBS (mg/dl) Baseline 146.6 + 22.7 94.29 + 8.2 90.3 + 12.3 0.00 
Post op 131.3 + 20.4 91.12 + 9.44 87.2 + 9.4 0.00 
 p Value 0.00 0.145 0.016  
HbA1c (%) Baseline 6.48 + 0.33 4.8 + 0.56 3.5 + 0.36 0.00 
Post op 6.07 + 0.30 4.65 + 0.52 3.50 + 0.33 0.00 
 p Value 0.00 0.00 0.49  
Total 
Cholesterol 
(mg/dl) 
Baseline 240.4 + 22.1 167.4 + 24.4 153.3 + 25.7 0.00 
Post op 210.6 + 28.3 167.4 + 20.4 145.1 + 24.6 0.00 
 p Value 0.00 0.231 0.00  
Triglycerides 
(mg/dl) 
Baseline 256.3 + 
57.41 
114.1 + 23.01 112.9 + 13.5 0.00 
Post op 225.08  + 
45.9 
111.7 + 20.7 108.2 + 13.9 0.00 
 p Value 0.00 0.00 0.002  
CBMN 
frequency (out 
of 1000 bi-
nucleated cells) 
Baseline 13.20 + 0.53 12.11 + 0.43 9.84 + 0.49 0.00 
Post op 12.80 + 0.46 11.87 + 0.50 9.6 + 0.45 0.00 
 p Value 0.00 0.00 0.03  
MDA (U/L) Baseline 3.41 + 0.29 2.73 + 0.47 1.14 + 0.33 0.00 
Post op 2.5 + 0.58 2.35 + 0.49 1.01 + 0.26 0.00 
 p Value 0.00 0.00 0.01  
Hs-CRP (mg/L) Baseline 8.77 + 0.54 6.9 + 0.51 1.21 + 0.33 0.00 
Post op 5.8 + 1.32 4.2 + 1.08 1.13 + 0.31 0.00 
 p Value 0.00 0.00 0.00  
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Table 4 shows comparison of clinical and laboratory data at baseline and after 3 
months. Mean PI score at baseline was 1.6 + 0.22 in group 1, 1.61 + 0.25 in group 2 
and 1.32 + 0.18 in group. This declined to 0.34 + 0.13 in group 1, 0.32 + 0.14, and 
0.27 + 0.06 in group 3. Intergroup comparison of post-operative PI score is 
statistically not significant. Similarly GI score also decreased dramatically from 
baseline to 3 months. Mean GI score at baseline was 1.8 + 0.26 in group 1, 1.74 + 
0.32 in group 2 and 1.31 + 0.28 in group. This declined to 0.41 + 0.19 in group 1, 
0.41 + 0.19 in group 2, and 0.36 + 0.39 in group 3. Other clinical parameters like 
Mean PPD and Mean CAL also decreased significantly after 3 months. Mean PPD at 
baseline was 4.49 + 0.37 in CP with DM group, 3.86 + 0.26 in CP group and 2.5 + 
0.20 in control group. This value reduced to 2.59 + 0.29 in CP with DM group, 2.4 + 
0.19 in CP group, and 2.5 + 0.19 in control group. Similarly Mean CAL at baseline 
was 4.80 + 0.37 in CP with DM group, 4.29 + 0.41 in CP group and 2.5 + 0.20 in 
control group. This value reduced to 2.97 + 0.30 in CP with DM group, 2.76 + 0.20 
in CP group, and 2.5 + 0.19 in control group. Intra group comparison reveals that 
significant reduction of PPD and CAL in group 1 and group 2 (p Value <0.05) but 
not in group 3. 
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TABLE 5: Differences in Metabolic, and Periodontal data of the participants at 
baseline and after 3 months [Mean (SD)] 
PARAMETERS GROUP 1 GROUP 2 GROUP 3 P VALUE 
PLAQUE INDEX 
(PI) 
1.3 + 0.2 1.2 + 0.2 1.07 + 0.2 0.001 
GINGIVAL 
INDEX (GI) 
1.4 + 0.2 1.2 + 0.2 1.0 + 0.4 0.00 
MEAN PPD (mm) 1.9 + 0.4 1.3 + 0.3 0.03 + 0.2 0.00 
MEAN CAL (mm) 1.8 + 0.4 1.5 + 0.5 0.02 + 0.2 0.00 
RBS (mg/dl) 16 + 20.9 2.8 + 9.2 2.8 + 5.5 0.001 
CBMN 
FREQUENCY 
(out of 1000 bi-
nucleated cells) 
0.38 + 0.35 0.27 + 0.21 0.15 + 0.24 0.014 
MDA LEVELS 
(U/L) 
0.88 + 0.59 0.39 + 0.28 0.15+ 0.16 0.00 
Hs-CRP (mg/L) 2.9 + 1.36 2.72 + 0.94 0.06 + 0.09 0.00 
HbA1C (%) 0.41 + 0.13 0.24 + 0.22 0.02 + 0.01 0.00 
TOTAL 
CHOLESTEROL 
(mg/dl)  
32.6 + 35.5 3.0 + 12.19 6.4 + 5.4 0.00 
TRIGLYCERIDES 
(mg/dl) 
25.6 + 26.3 4.4 + 3.73 3.6 + 5.4 0.00 
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Table 5 shows the amount of reduction occurred in Periodontal as well as 
laboratory parameters from baseline to 3 months post operatively.  Mean PI and 
Mean GI scores reduced significantly in all the three groups. Mean PI score 
reduction is 1.3 + 0.2 in CP with DM group, 1.2 + 0.2 in CP group and 1.07 + 0.2 in 
control group. PI score reduction occurs more in group 1 and group 2 than group 3. 
Similarly GI score reduction is 1.4 + 0.2 in CP with DM group, 1.2 + 0.2 in CP 
group and 1.0 + 0.4 in control group. Intergroup comparison reveals Mean PPD and 
Mean CAL reduction occurs more in CP with DM and CP group than in control 
group. Random blood sugar, Total Cholesterol and Triglyceride levels reduced 
significantly in all the groups. But more reduction occurs in CP with DM group than 
CP and control group. Reduction of Mean CBMN frequency, MDA and Hs-CRP 
occurs more in CP with DM followed by CP group and finally least reduction occurs 
in control group. 
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GRAPH 1: COMPARISON OF MEAN PI SCORE OF 
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GRAPH 2: COMPARISON OF MEAN GI SCORE OF 
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GRAPH 5: COMPARISON OF MEAN RBS VALUE OF 
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GRAPH 6: COMPARISON OF MEAN TOTAL CHOLESTEROL 
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GRAPH 7: COMPARISON OF MEAN TRIGLYCERIDE 
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GRAPH 9: COMPARISON OF MEAN CBMN FREQUENCY OF 
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MONTHS 
BASELINE
3 MONTHS POST OP
0
0.5
1
1.5
2
2.5
3
3.5
GROUP 1 GROUP 2 GROUP 3
M
E
A
N
 M
A
L
O
N
D
IA
L
D
E
H
Y
D
E
 (
U
/L
) 
GRAPH 10: COMPARISON OF MEAN MALONDIALDEHYDE 
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Periodontitis is a chronic infectious disease, which is usually initiated by an 
imbalance between the oral microbial community and host immuno-inflammatory 
response. The initial host response is the release of reactive oxygen species (ROS) 
via the metabolic process of respiratory burst in the Polymorphonuclear leukocytes 
(PMNL’s), macrophages and monocytes. Excessive production of these ROS results 
in oxidative stress in the body. Diabetes mellitus, for many years, has been 
recognized as an important risk factor for periodontal diseases and is associated with 
significantly higher prevalence and severity of periodontitis. In both the diseases 
there is increased ROS production. Among the ROS formed, H2O2 and OH radicals 
are potent oxidants that can affect nucleic acids and modify bases in the DNA, 
contributing to an increase in DNA damage and therefore Micronuclei formation.
12
 
Micronuclei were first described by Howell and Jolly in late 1800’s and early 1900’s 
as Feulgen positive nuclear bodies in human reticulocytes, representing 
chromosomes separated from the mitotic spindle
66
.  
The aim of the current study was to compare the micronuclei frequency in 
peripheral blood, serum Malondialdehyde level, and serum high sensitive C - 
reactive protein at baseline and 3 months after non-surgical periodontal therapy in 
chronic periodontitis patients with and without well controlled type 2 diabetes 
mellitus, and the patients with healthy periodontium. 
In the present study total of 83 patients were selected at baseline. Twenty 
eight Chronic periodontitis patients with well controlled type 2 DM (Mean age 48.4 
+ 6.9), Twenty seven Chronic periodontitis patients (Mean age 36.9 + 5.5) and 
Twenty eight Healthy controls (Mean age 32.7 + 2.5) were enrolled in this study. Of 
which 75 patients completed the three months protocol. 
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In the present study at baseline all the periodontal parameters like PI, GI, 
PPD, and CAL were elevated in group 1 and group 2 than group 3. There was no 
statistical difference in PI, GI at baseline among three groups. In terms of mean PPD 
and mean CAL was more in DM group compared to CP group. In other words 
chronic periodontitis with well controlled type 2 DM had more periodontal 
breakdown than in patients with chronic periodontitis alone. This shows that DM 
has additional effect on periodontium. 3 months after SRP all the clinical parameters 
are reduced significantly in all the groups. These findings were consistent with 
previous study by Kudva et al 2010 found out that highly significant reduction in the 
plaque index scores, Gingival index, and Probing pocket depth was seen in both the 
control and test groups from baseline to 3 months.
67 
Similarly other studies also 
found out statistically significant reduction in plaque score, gingival index score, 
probing pocket depth and mean CAL after non-surgical periodontal treatment from 
baseline to 3 months.
68-69 
The results of the present study demonstrated a positive 
correlation between PI, GI, probing depth and clinical attachment level with other 
laboratory parameters. 
In the present study the 3-months interval was chosen because glucose in 
blood is irreversibly bound to haemoglobin. The glycated haemoglobin indicates the 
glucose status during at least half of the life of Red blood cells that is 30 to 90 days 
because the half-life of blood cells is 120 days.
70 
 
After treatment, there were improvements in all of the monitored clinical 
parameters. These improvements were reflected at the systemic level by alterations 
in serum inflammatory markers and as verified in previous studies, a reduction in 
HbA1c. Clinical trial by Agarwal et al 2016 provided evidence that elimination of 
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periodontal inflammation, significantly (P < 0.05) reduce the HbA1c level, thus 
improving diabetic metabolic control.
71 
Similarly study by Aryal et al 2017 suggest 
that following periodontal therapy there was an improvement in glycemic control in 
individuals with type 2 DM when compared with a non-treatment control group.
44 
In our study HbA1c level reduced 0.41 + 0.13 in CP with DM group. Recent 
systematic review and meta-analysis by Teshome et al 2017 concluded that mean 
HbA1c reduction after periodontal treatment was 0.51%.
42  
Similarly another systematic review by Corbella et al 2013 found out that the 
mean decrease of HbA1c after periodontal treatment was 0.38% after 3 months and 
0.31% after 6 months
48
. Another study by Kanduluru et al 2014 stated that, three 
months after SRP 0.35% reduction of HbA1c occurs in chronic periodontitis patients 
with type 2 diabetes mellitus
18
. 
In the present study significant elevated levels of mean CBMN frequency in 
CP with DM group and CP alone group compared to control group. Consistent 
findings are also found by Rathod et al 2016
12
, concluded that patients with chronic 
periodontitis and DM had increased CBMN frequency. Another study by Zamora-
Perez et al 2015 concluded that micronuclei frequency was elevated in buccal 
mucosal cells of chronic periodontitis patients.
22 
Results by Bastos-Aires et al 2013 
indicated a 2.3-fold increase in MN basal levels in patients with moderate to severe 
periodontitis compared to the control patients (P < 0.001), suggesting that the 
periodontal status may affect MN reference levels.
23 
Shettigar et al 2012 found out that increased glycosylation seems to induce 
oxidative damage in the DNA of the diabetic patients, which manifests as an 
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increased micronuclei frequency
25
. Zuniga-Gonzalez et al 2007 demonstrated that 
either controlled (glycosylated haemoglobin levels >7%) or uncontrolled diabetic 
patients (glycosylated haemoglobin levels <7%) had 2-fold higher frequency of 
MNs in buccal mucosa samples than healthy subjects.
26 
In our study we used peripheral lymphocytes for assessing the micronuclei 
frequency instead of taking saliva or GCF or buccal mucosal cells because these 
sources have following disadvantages; (i) Saliva and GCF have storage difficulties, 
(ii) Systemic effects cannot be measured in these locally expressed fluids, (iii) Any 
radiation exposure to oral cavity can cause MN formation in buccal mucosal cells, 
which could lead to mis-interpretation of results, (iv) Very less quantity of GCF can 
be obtained. 
Also in our study we selected the patient with well controlled type 2 DM 
(HbA1c value 6.5-7.0%) for group 1 rather than poorly controlled diabetics. Because 
uncontrolled DM causes more periodontal destruction, thus we cannot differentiate 
the reasons for the elevated levels of biomarkers. Also periodontal therapy is less 
effective in poorly controlled diabetic subjects and bad metabolic control could 
reveal a failure of pharmacological and non-pharmacological measures of disease 
control
72
. In our study we have not used any adjunctive antibiotic therapy other than 
scaling and root planing to all the participants. Because using systemic/local 
antibiotic therapy could affect the clinical results.  
After three months of non-surgical periodontal therapy, mean CBMN values 
reduced statistically significant in all the three groups (p Value <0.05). To the best 
of our knowledge this is the first study which evaluated the effect of non-surgical 
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periodontal treatment on CBMN frequency in Diabetic chronic periodontitis 
patients. 
Excessive production of ROS results in oxidative stress in the body. Reactive 
oxygen species (ROS) have a very short life (10
-6
-10
-9
 seconds), so it is not easy to 
detect its presence. The ROS-mediated tissue destruction could be measured by the 
final product of lipid peroxidation (LPO), such as malondialdehyde (MDA).
1 
In our study mean MDA level was elevated in CP with DM group and CP 
alone group than control group. Among these CP with DM group showed increased 
MDA level than CP alone group. These results are consistent with previous studies 
suggesting that increased MDA levels in chronic periodontitis and DM
1, 30, 73, 74
. 
The main mechanism behind the elevation of MDA is the disturbance in anti-
oxidant defense system due to overproduction of LPO products at inflammatory 
sites. This could be related to a higher level of oxidative stress in periodontitis and 
diabetes patients
1
.
 
After three months of non-surgical periodontal therapy mean 
MDA levels were reduced in all the groups. This reduction was statistically 
significant (p Value <0.05).  
Random blood sugar and total cholesterol also reduced in all the groups but 
the reduction was statistically significant in group 1 and group 3 not in group 2. 
Triglycerides also declined significantly in all the groups. Similarly, many other 
studies have reported that total cholesterol and triglyceride levels in patient with 
chronic periodontitis were significantly higher than those of the healthy subjects
75, 
76
. Jaramillo et al 2013 stated that untreated periodontitis is associated to possible 
alterations of lipid metabolism
77
.  
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Tendon et al
78
 evaluated the effect of periodontal disease on the serum lipid 
levels and found that periodontal therapy resulted in significant decrease in the 
levels of serum total cholesterol, trigycerides and LDL-cholesterol.  
They also stated that the underlying mechanism may be the local production 
of inflammatory cytokines and its effect on other systemic mediators leading to 
alterations in lipid metabolism, such as increased LDL and triglycerides, due to 
increased hepatic lipogenesis, lipolysis from adipose tissue, or reduced blood 
clearance
78
. 
 In our study 3 months after periodontal treatment total cholesterol and 
triglyceride levels reduced significantly. This is because of the fact that non-surgical 
periodontal therapy reduces the systemic inflammatory burden. 
 C - reactive protein (CRP) is a plasma protein, pentameric in nature, which 
participates in systemic response to inflammation. Its homologoes are formed in 
vertebrates and many invertibrates. It has extremely high sensitivity but very poor 
specificity.
79 
CRP is known to be produced primarily in the liver, synthesized by 
hepatocytes in response to inflammatory cytokines particularly IL-6. It reaches peak 
levels quickly in approximately 50 hours, and falls once the inflammatory stimulus 
is removed and has a half-life of 18 hours.
80 
 
All studies on periodontitis patients with diabetes clearly demonstrate that 
the inflammatory response in such patients is related to an increase in CRP
13
.
 
In our 
study Hs-CRP levels were significantly elevated in group 1 and group 2 than group 
3. Recent investigations emphasized the role of moderate elevation of CRP levels as 
a risk factor for cardiovascular diseases
14
. Mechanism behind the CRP increase in 
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our study is that the periodontitis and DM contributes to the elevation of systemic 
inflammation.  
 After 3 months of non-surgical periodontal therapy, mean Hs-CRP levels 
reduced significantly in all the groups (p Value <0.05). This is consistent with the 
previous studies, reporting that effective non-surgical periodontal treatment can 
reduce the serum Hs-CRP levels in chronic periodontitis patients with type 2 
diabetes mellitus
15, 49
. Similarly a study by Marcaccini et al 2009 found out that, IL-
6 and Hs-CRP concentrations decreased 3 months after non-surgical periodontal 
therapy in patients with periodontal disease
53
. 
 Similarly systematic reviews by Demmer et al 2013, de Freites et al 2012, 
and Ioannidou et al 2006 also reported that there was a significant reduction of 
systemic CRP following periodontal treatment
81-83
. 
 Increased Micronuclei frequency, MDA, and Hs-CRP levels were linked 
with many cardiovascular diseases. Andreassi et al 2011 stated that an elevated level 
of MDA indicates increase in production of oxygen free radicals suggesting the 
possible risk in atherogenesis, leading to coronary heart diseases
16
. HsCRP is a 
powerful marker of vascular risk in a wide range of populations and, as such, is a 
powerful research tool in assessing at-risk populations. Determination of these 
markers contributes to understanding the development of and prevention of CVS 
disorders
17
. Our study results demonstrate that chronic periodontitis patients with 
well controlled type 2 DM have increased risk of cardiovascular diseases at baseline. 
After three months of non-surgical periodontal therapy all the biomarker levels were 
reduced due to the elimination of inflammatory burden. This helps to reduce the 
Discussion 
 
   Page 53 
 
cardiovascular risk of the patients with chronic periodontitis and type 2 DM. Early 
detection of these biomarkers will help the clinician to plan the treatment 
accordingly to reduce the occurrence of cardiovascular events. The findings of the 
current study demonstrated that periodontal therapy brought about significant 
changes in the clinical as well as laboratory parameters of study subjects reinforcing 
the hypothesis that there is an inter-relationship between periodontitis, DM and 
cardiovascular diseases. 
 The present study has some of the limitations that need to be clearly 
discussed which include, the short duration of the follow up (3 months). Further 
longitudinal studies are necessary to rule out the perio-systemic association. Also, 
the current study was cross sectional in nature with a modest sample size and cannot 
be used to determine the causal relationship. Thus, cohort studies with large sample 
sizes should be conducted to obtain comprehensive information. The calibration of 
the examiner who performed clinical examination was not carried out. Thus, the 
effectiveness of this procedure might be biased. 
 
  
 
 
 
 
 
 
 
 
 
 
Summary & Conclusion  
Summary and Conclusion 
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Present study compares the MN frequency, serum MDA and serum Hs-CRP 
levels in chronic periodontitis patients with and without well controlled type 2 diabetes 
mellitus and healthy controls at baseline and 3 months after non-surgical periodontal 
therapy. All the clinical and laboratory parameters were elevated at baseline in all the 
groups. Elevated levels of these bio markers indicate the patient is under cardiovascular 
risk.  After three months of non-surgical periodontal therapy all the biomarker levels 
were reduced due to the elimination of inflammatory burden. The findings of the 
current study demonstrated that periodontal therapy brought about significant 
changes in the clinical as well as laboratory parameters of patients with chronic 
periodontitis and well controlled type 2 diabetes mellitus. This helps to reduce the 
cardiovascular risk of the patients with chronic periodontitis and type 2 DM. 
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CONSENT FORM 
PART 1 OF 2 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
 
 
 
 
 
1. Name of the Principal Investigator :Dr. Blessing Emmanuel P 
                                             Second Year Post Graduate student  
                                             Department of Periodontics 
                                             Sree Mookambika Institute of Dental Sciences, 
                                             Kulasekharam 
2. Name of the Guide: Dr. Arun Sadasivan   MDS 
                               Professor 
                               Department of Periodontics  
                               Sree Mookambika Institute of Dental Sciences 
                               Kulasekharam, Kanyakumari District-629161  
3. Name of the Co-Guide: Dr. Elizabeth Koshi MDS 
                                     Professor and Head 
                                     Department of Periodontics 
                                     Sree Mookambika Institute of Dental Sciences 
                                     Kanyakumari District-629161   
4. Institute: Sree Mookambika Institute of Dental Sciences, 
 V.P.M Hospital complex, Padanilam,  
 Kulasekharam, Kanyakumari District – 629161 
 Tamilnadu 
Dear Volunteers, 
We welcome you and thank you for your keen interest in participation in 
this research project. Before you participate in this study, it is important for you to 
understand why this research is being carried out. This form will provide you all the 
relevant details of this research. It will explain the nature, the purpose, the benefits, the 
risks, the discomforts, the precautions and the information about how this project will 
be carried out. It is important that you read and understand the contents of the form 
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5. Title of the study: “EFFECT OF NON SURGICAL PERIODONTAL 
THERAPY ON THE MICRONUCLEI FREQUENCY, SERUM 
MALONDIALDEHYDE AND SERUM HIGH SENSITIVE C – REACTIVE 
PROTEIN LEVELS IN CHRONIC PERIODONTITIS PATIENTS WITH AND 
WITHOUT WELL CONTROLLED TYPE 2 DIABETES MELLITUS” 
 
6. Background information: 
Periodontitis is a multifactorial disease which is mainly caused by pathogenic bacteria. 
Polymorphonuclear leukocytes (PMNs) are the primary mediators of host response 
against pathogens and they generate increased levels of reactive oxygen species (ROS). 
The ROS-mediated tissue destruction could be measured by the final product of lipid 
peroxidation (LPO), such as malondialdehyde (MDA). Type 2 diabetes mellitus is the 
most common form of DM One of the main consequences of this adverse action is the 
formation of oxidative stress.2The oxidative stress is intrinsically related to the 
pathogenesis of type 2 diabetes, dyslipidemia and PD, and it leads to DNA damage. 
 
7. Aims and Objectives 
The aim of the study is to evaluate the effect of non-surgical periodontal therapy on 
the micronuclei frequency, serum malondialdehyde and serum hs – CRP levels in 
chronic periodontitis patients with and without well controlled type 2 diabetes 
mellitus and healthy controls. 
8. Scientific justification of the study:                      
 Oxidative stress induces cellular damage and insulin resistance, and emerges 
as the major mechanisms for related co-morbidities. Oxidative stress is intrinsically 
related to the pathogenesis of type 2 diabetes, dyslipidemia and PD, and it leads to 
DNA damage. One of the most established methods for evaluating DNA damage is 
the micronucleus (MN) test. The MN test analysis is based on the identification of a 
secondary nucleus. 
 Polymorphonuclear leukocytes (PMNs) are the primary mediators of host 
response against pathogens in periodontal disease and they generate increased levels 
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of reactive oxygen species (ROS). The ROS-mediated tissue destruction could be 
measured by the final product of lipid peroxidation (LPO), such as malondialdehyde 
(MDA). 
 High sensitive c – reactive protein is an acute phase protein which is elevated 
during inflammatory diseases and certain cardiovascular diseases. 
 
9. Procedure for the study:  
 The parents and subjects are explained about the research and their informed 
consent obtained for using blood sample (which were taken for routine examination 
for diabetes) for the study. 
 Then you will be undergoing periodontal examination that involves the 
evaluation of gums as well as the amount of plaque present in the teeth. 
 Collect fresh blood by venepuncture and transfer to heparinised vacutainers. 
 Collected blood samples send on the same day to Genetika centre for 
advanced genetic studies, Pettah, Thiruvananthapuram, kerala. Collected blood 
samples will be discarded immediately after assessing the lab parameters. 
 The confidentiality of the patient’s data will also be maintained. 
 
10. Expected risks for the participants: 
                         Nil 
11. Expected benefits of research for the participants: 
 There is no direct benefit to you.  The Collected 6ml blood sample will be 
used only for research purpose by a recognized Research Center (Genetika centre for 
advanced genetic studies, Pettah, Thiruvananthapuram, Kerala) without any loss of 
details regarding patient and sample collected.  
 The study will help the health care practitioners to understand the role of 
non-surgical periodontal therapy on the micronuclei formation and elevated MDA 
levels in Type 2 diabetes mellitus and chronic periodontitis. 
 Elevated concentrations of these markers were linked with a more frequent 
occurrence of cardiac events so early detection of these biomarkers help the clinician 
to plan the treatment thereby improving patient survival rate. 
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12. Maintenance of confidentiality: 
a. You have the right to confidentiality regarding the privacy of your medical 
information 
             (Personal details, results of physical examinations, investigations, and your medical 
history) 
b. By signing this document, you will be allowing the research team 
investigators, other study Personnel, sponsors, institutional ethics committee and any 
person or agency required by law to view your data, if required.  
c. The results of study performed as part of this research may be included in 
your medical record.  
d. The information from this study, if published in scientific journals or 
presented at scientific meetings, will not reveal your identity. 
 
13. Why have I been chosen to be in this study? 
a. Chosen because of grouping under the inclusion and exclusion criteria  
b. Need of good sampling size 
c. No invasive procedure that harm your health and it  helps in diagnosis and 
helpful for the society 
 
14. How many people will be in the study? 
           75  
15. Agreement of compensation to the participants (In case of a study 
related injury):  
No related injury anticipated. Patient will be taken care in case of complication and   
medical treatment will be provided. 
16. Can I withdraw from the study at any time during the study period? 
 The participation in this research is purely voluntary and you have the right 
to withdraw from this study at any time during the course of the study without 
giving any reasons.  
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 However, it is advisable that you talk to the research team prior to stopping 
information. 
17. If there is any new findings/information, would I be informed?   
           Yes 
 
18. Expected duration of the participant’s participation in the study? 
    One year 
 
19. Whom do I contact for further information? 
 
 
 
 
 
 
 
 
 
Place:  
Date:               Signature of Principal Investigator 
 
 
 
 
Signature of the participant 
 
 
 
For any study related queries, you are free to contact: 
Dr. Blessing Emmanuel P, 
Post graduate Student, 
Department of Periodontics  
Sree Mookambika Institute of Dental Sciences 
Kulasekharam, KanyaKumari District-629161 
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k½X ]{Xw þ `mKw þ 1 
]T\hpambn klIcn¡p¶ hyànIfpsS Adnhntebv¡v 
 
{]nbs¸« k¶² tkhI³ / tkhI, 
 R§Ä \n§sf kzmKXw sN¿p¶p.  AtXmsSm¸w Cu ]T\hpambn klIcn¡m\pÅ 
k¶²XtbmSv \µn tcJs¸Sp¯p¶p.  \n§Ä Cu ]T\¯nÂ ]s¦Sp¡p¶Xn\p ap³]v Cu ]T\w  
F´n\mWv \S¯s¸Sp¶Xv F¶v Andtb­Xp­v. AXn\mÂ Cu t^md¯nÂ  KthjW ]T\¯nsâ 
hnhc§fpw aäpw  hniZambn tcJs¸Sp¯nbncn¡p¶p.  Cu ]T\¯nsâ coXn, Dt±iw, {]tbmP\w, 
A]ISkm²yX, t¢iw, ap³IcpXÂ, F§s\ Cu ]T\w  ap³t]m«p sIm­pt]mIp¶p F¶n§s\  FÃm 
hnhc§fpw  t^md¯nÂ  tcJs¸Sp¯nbncn¡p¶p.  kZbw Cu  hnhc§Ä  hmbn¨p a\Ênem¡phm³  
A`yÀ°n¡p¶p.  Cu hnhc§fnÂ imkv{X]camb ]Z§Ä DÅXn\mÂ  kwib\nhmcW¯n\p {][m\ 
]T\IÀ¯mhnt\mtSm Xmsg tcJs¸Sp¯n bncn¡p¶ hyànItfmtSm t^mdw H¸nSp¶Xn\p ap³t]m 
AsÃ¦nÂ Cu ]T\¯nsâ Imemh[n Xocp¶Xphtctbm kao]n¡mhp¶XmWv.  
1. apJy KthjI³  :  tUm. ബല്സിങ ്ഇമമ്ാനുവ  പി. 
    t]mÌp{KmPpthäv 
    Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv   
      {io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kv, 
    IpetiJcw þ 629161 
    t^m¬: 7598197350    
2. {][m\ amÀ¤ZÀin  : tUm.Acp¬ kZminh³ 
s{]m^kÀ 
Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv  
{io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kkv, 
IpetiJcw. 
t^m¬: 9847246961    
3. kl amÀ¤ ZÀin  : tUm. Fenks_¯v tImin 
slUv Hm^v Zn Un¸mÀ«vsaâv, 
Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv  
{io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kkv, 
IpetiJcw. 
t^m¬:  9447154335 
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4. C³Ìnäyq«v  : {io. aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kkv 
    ]S\new, IpetiJcw, 
    I\ymIpamcn þ 629161. 
    Xangv\mSv.  
5. ]T\¯nsâ ioÀjIw:  
 രക്തത്തി  ഉള്ള മൈക്രോന്യൂക്ളിയ, മലോനാ ഡിഹൈഡ്, എച്.സ.്സി.ആ .പി എന്നിവയുടെ അളവുക  
പ്രമേഹം ഉള്ളവരും ഇല്ലാത്തവരുമായ പെരിയോഡോന്റിറ്റിസ് രോഗികളി : ഒരു ടെസ്റ്റ് ട്യൂബ് പഠനം  
6. ]Ým¯e hnhcw ? 
 പെരിയോഡോന്റിറ്റിസ് എന്ന രോഗം പല കാരണങ്ങളാ  ഉണ്ടാകുന്നു എങ്കിലും പ്രധാന കാരണം കീടാണു 
ആണ്. പി. എം  സ്  എന്ന കോശങ്ങ   ഇ രോഗത്തിന് എതിരായി  റിയാക്ടീവ് ഓക്സിജ  സപ്ീഷിസ് എന്ന രാസവസ്തു 
ഉണ്ടാക്കുന്നു . ഇവ ശരീരത്തി  ഉണ്ടാക്കുന്ന ദോഷവശങ്ങ  അറിയുന്നതിനായി ലിപിഡ് പെറോക ്സിഡേഷ  എന്ന 
പ്രക്രിയയുടെ അവസാന ഫലമായി ഉണ്ടാകുന്ന മാലോനാ ഡിഹൈഡ് എന്ന രാസവസ്തുവിന്റെ അളവുക  നമ്മെ 
സഹായിക്കുന്നു.ഓക്സിഡേറ്റീവ് സ്ട്രെസ് ടൈപ്പ് 2 ഡയബെറ്റിസ്, കൊലെസ്റ്ററോ  , പെരിയോഡോന്റിറ്റിസ് 
എന്നീ രോഗങ്ങ ക്ക് കാരണമായി ഡി.  . എ യെ നശിപ്പിക്കുന്നു.  
7. e£y§fpw Dt±i§fpw 
 പ്രമേഹം ഉള്ളവരും  ഇല്ലാത്തവരുമായ പെരിയോഡോന്റിറ്റിസ് രോഗികളി  താഴെ പറയുന്ന അളവുക  
കണ്ടുപിടിക്കുക.: 
1.  മൈക്രോന്യൂസല്െയ്  
2. മാലോനാ ഡിഹൈഡ് 
3. എച് സ് സി   പി  
8. KthjWw \S¯m\pÅ \ymboIcWw 
 ഓക്സിഡേറ്റീവ് സ്ട്രെസ് ടൈപ്പ് 2 ഡയബെറ്റിസ്, കൊലെസ്റ്ററോ  , പെരിയോഡോന്റിറ്റിസ് എന്നീ 
രോഗങ്ങ ക്ക് കാരണമായി ഡി.  . എ യെ നശിപ്പിക്കുന്നു. ഈ  ഡി   എ നാശം അളക്കുന്നതിനായി 
മൈക്രോന്യൂസ്ലെയ് ടെസ്റ്റ് സഹായിക്കുന്നു.  
 പി. എം  സ്  എന്ന കോശങ്ങ    രോഗത്തിന് എതിരായി  റിയാക്ടീവ് ഓക്സിജ  സ്പീഷിസ് ഉണ്ടാക്കുന്നു. 
ഇവ ശരീരത്തി  ഉണ്ടാക്കുന്ന ദോഷവശങ്ങ  അറിയുന്നതിനായി ലിപിഡ് പെറോക ്സിഡേഷ  എന്ന പ്രക്രിയയുടെ 
അവസാന ഫലമായി ഉണ്ടാകുന്ന മാലോനാ ഡിഹൈഡ് എന്ന രാസവസ്തുവിന്റെ അളവുക  നമ്മെ സഹായിക്കുന്നു. 
9. ]T\ coXn  
 നിങ്ങളുടെ മുഴുവ  വിവരങ്ങളും അടങ്ങിയ കേസ് ചാ ട് രേഖപെടുത്തുന്നതാവും. ആവശ്യമെങ്കി  
പരിശോധന നടത്തപ്പെടുന്നതാണ.് പെരിയോഡോന്റിയതിന്റെ പരിശോധന വേളയി  5  എം   രക്തം ഒരു സിറിഞ്ചും 
നീഡിലും ഉപയോഗിച്ച് ശേഖരിക്കുന്നതാണ്. അതിനുശേഷം രക്തത്തിലെ പഞ്ചസാരയുടെ അളവും പ്ലാസ്മയിലെ 
മൈക്രോന്യൂസ്ലെയ്, മാലോനാ ഡിഹൈഡ്,എച് സ് സി   പി എന്നീ വസ്തുക്കളുടെ അളവുക  പരിശോധിക്കും. 
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 പരിശോധനയ്ക്കു ശേഷം ശേഖരിച്ച രക്തവും താങ്കളെ കുറിച്ച് രേഖപ്പെടുത്തിയിരിക്കുന്ന ഒരു 
വിവരങ്ങളും ഒരു രീതിയിലും ചോ ന്നുപോകാതെ ജനിറ്റിക്ക ലബോറട്ടറി, തിരുവനന്തപുരത്തു 
സൂക്ഷിക്കുന്നതായിരിക്കും. 
10. {]Xo£n¡p¶ A]IS km²yXIÄ   þ  
 Cu ]T\¯nsâ {]hr¯\coXn aqeapÅ  A]IS km[yX hfsc IpdhmWv. 
apdnhnÂ \nt¶m, sXmen¡SnbnÂ \nt¶m DÅ sNdnb  cà{kmhw, ho¡w, sNdnb thZ\ 
F¶nhbmWv A]IS  km[yXIÄ. Ch kpNnh¨ kvYe¯nÂ sNdnb k½À±T 
sNep¯nbmÂ km[rIcn¡s¸SpT.   
11. Cu ]T\¯nÂ ]s¦Sp¡p¶XpsIm­v F\n¡v Fs´¦nepw  D]tbmKapt­m ? 
 താങ്ക ക്കു നേരിട്ട് ഒരു ഉപയോഗവും ഇല്ല. ശേഖരിച്ച രക്തം പഠന ആവശ്യങ്ങ ക്കായി 
ഉപയോഗിക്കപ്പെടുന്നതാരിക്കും. 
12. Rm³ Cu ]T\¯nÂ ]s¦Sp¡p¶ hnhcw clkyambn hbv¡ptam ? 
 \n§fnÂ \n¶v  tiJcn¡p¶  FÃm hnhc§fpw  clkyambn hbv¡p¶Xmbncn¡pw \n§sf 
]änbpÅ hnhc§Ä BtcmSpw shfns¸Sp¯p¶Xmbncn¡nÃ.  `mhnbnÂ Cu ]T\w imkv{XteJ\ambn 
{]kn²oIcn¡pt¼mÄ \n§fpsS t]cn\p ]Icw tImUv BWv D]tbmKn¡pI.  
 
13. Fs¶ F´psIm­v Cu ]T\¯nÂ DÄs¸Sp¯n ? 
 \n§Ä¡v s]cntUmssâkv F¶ AkpJw DÅXpsIm­v \n§sf Cu ]T\¯nÂ 
DÄs]Sp¯nbncn¡p¶p. 
14. F{X BfpIÄ Cu ]T\¯nÂ DÄs¸Sp¶p.    75 
15. \ã]cnlmc DS¼Sn  
 ]T\hntZbambn GsX¦nepw Xc¯nÂ tcmKw k¦oÀ®ambmÂ tcmKnsb Cu Øm]\¯nÂ 
hnZKvZNnInÕbv¡v hnt[b\m¡p¶XmWv.  
16. GsX¦nepw hn[¯nÂ thX\w e`n¡ptam    þ CÃ 
17. Ft¸mÄ thWsa¦nepw  F\n¡v  Cu ]T\¯nÂ \n¶v  ]n³amdmtam  
 Cu ]T\¯nÂ  ]s¦Sp¡Wtam th­tbm F¶p Xocpam\n¡m\pÅ ]qÀ®  AhImiw 
\n§Ä¡p­v.  \n§Ä CXnÂ  ]s¦Sp¡phm³ Xocpam\n¨mÂ  Hcp k½X]{X¯nÂ H¸n«v \ÂtI­Xp­v. 
Cu ]T\¯nÂ  \n¶v GXp kabhpw ]n³hm§m\pÅ  kzmX{´yhpw \n§Ä¡p­v.  CXv \n§fpsS  aäp 
NnInÕIsf bmsXmcp hn[¯nepw _m[n¡p¶Xmbncn¡nÃ.  
18. Cu KthjW¯nsâ ^eambn ]pXnb Fs´¦nepw  Is­¯epIfps­¦nÂ 
AXv Fs¶ Andbn¡ptam ? 
 Cu ]T\¯nsâ  Is­¯epIÄ ]T\ Ahkm\w \n§sf Andbn¡p¶Xmbncn¡pw.  
19. Cu ]T\¯nsâ  kab ssZÀLyw F{XbmWv ? 
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 GItZiw aq¶p amkw 
 
 
20. IqSpXÂ  hnhc§Ä¡mbn Xmsg ]dbp¶hsc \n§Ä¡v  _Ôs¸Smhp¶XmWv. 
    tUm. ബല്സിങ ്ഇമമ്ാനുവ  പി 
    t]mÌp{KmPpthäv 
    Un¸mÀ«vsaâv Hm^v s]cntbmtUmânIvkv   
     {io aqImw_nI C³Ìnäyq«v Hm^v sUâÂ kb³kv, 
    IpetiJcw þ 629161. 
Mob – 7598197350 
Email  – blessybds@gmail.com 
Øew:  
XobXn : 
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ஒᾺᾗத᾿ வாᾰᾁᾚலΆ 
ᾙத᾿ பாகΆ 
பᾱேகιபாள᾽கᾦᾰᾁ ஆᾼவிைன ᾁறிᾷத தகவ᾿ 
அᾹபா᾽Ᾰத பᾱேகιபாள᾽கேள, 
இᾸத ஆᾼவி᾿ பᾱᾁெபιறதιᾁ உᾱகைள வரேவιகிேறாΆ  .இதி᾿ 
பᾱᾁெபᾠவதιᾁ ᾙᾹᾗ இᾸத ஆᾼᾫ எதιகாக நடᾷதᾺபᾌகிறᾐ எᾹபைத நீᾱக῀ 
அறிᾸᾐ ெகா῀ள ேவᾶᾌΆ .இᾸத ஆᾼவிᾹ நᾹைம தீைமக῀ பιறி இᾸத பᾊவΆ 
விளᾰᾁகிறᾐ  .இᾸத ஆவணᾱகைள கவனமாக பᾊᾷᾐ ᾗாிᾸᾐ ெகா῀ᾦத᾿ 
அவசியΆ .இᾸத ஆᾼவி᾿ பயᾹபᾌᾷதᾺபᾌΆ அறிவிய᾿ வா᾽ᾷைதகளி᾿ உᾱகᾦᾰᾁ 
சᾸேதக இᾞᾰᾁெமᾹறா᾿ ᾙதᾹைம ஆᾼவாளைர ேநாிேலா அ᾿லᾐ கீேழ 
ெகாᾌᾰகᾺப᾵ᾌ῀ள ெதாைலேபசி எᾶணிேலா அ᾿லᾐ மிᾹனᾴச᾿ வழியாகேவா 
ெதாட᾽ᾗ ெகா῀ளலாΆ. 
1. ᾙதᾹைம ஆᾼவாளாிᾹ ெபய᾽ 
டாᾰட᾽. பிளசிᾱ இΆமாᾔேவ᾿ ᾖ  
ᾙᾐநிைல ப᾿ மᾞᾷᾐவ மாணவ᾽  
ப᾿ மιᾠΆ ஈᾠ ேநாᾼபிாிᾫ 
ᾯ ᾚகாΆபிகா ப᾿ மᾞᾷᾐவᾰ க᾿ᾤாி  
ᾁலேசகரΆ  
2. வழிகா᾵ᾊயிᾹ ெபய᾽  
டாᾰட᾽. அᾞᾶ சதாசிவᾹ எΆᾊஎῄ 
ேபராசிாிய᾽  
ப᾿ மιᾠΆ ஈᾠ ேநாᾼபிாிᾫ 
ᾯ ᾚகாΆபிகா ப᾿ மᾞᾷᾐவᾰ க᾿ᾤாி  
ᾁலேசகரΆ 
3. இைண வழிகா᾵ᾊ  
டாᾰட᾽. எᾢசெபᾷ ேகாஷி எΆᾊஎῄ 
ᾙதᾹைம ேபராசிாிய᾽  
ப᾿ மιᾠΆ ஈᾠ ேநாᾼபிாிᾫ 
ᾯ ᾚகாΆபிகா ப᾿ மᾞᾷᾐவᾰ க᾿ᾤாி  
ᾁலேசகரΆ 
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4. க᾿ᾥாியிᾹ ெபய᾽  
ᾯ ᾚகாΆபிகா ப᾿ மᾞᾷᾐவᾰ க᾿ᾤாி  
ᾁலேசகரΆ 
கᾹனியாᾁமாி மாவ᾵டΆ  
 
5. ஆராᾼᾲசியிᾹ தைலᾺᾗ  
“அᾠைவ சிகிᾲைச இ᾿லா ெபாிேயாடாᾶட᾿ சிகிᾲைசயிᾹ தாᾰகᾷைத 
ைமᾰேரா நிᾝᾰளிைய, ஆᾰᾭேடᾊῂ ῄ᾵ெரῄ பாதிᾺைப ேமலனா᾿ᾊைஹᾌ 
மιᾠΆ சி ாியᾰᾊῂ ᾺேராᾋᾹ ᾚலΆ ெபாிேயாடாᾹᾊᾊῄ ேநாயாளிக῀ மιᾠΆ 
ெபாிேயாடாᾹᾊᾊῄ மιᾠΆ நீாிழிᾫ வைக இரᾶᾌ உ῀ள ேநாயாளிகளிடᾙΆ 
கᾶடறித᾿” 
 
6. ᾁறிᾰேகா῀ 
ᾊᾹஏ பாதிᾺைப ைமᾰேரா நிᾝᾰளிைய ᾚலᾙΆ ஆᾰᾭேடᾊῂ ῄ᾵ெரῄ 
பாதிᾺைப ேமலனா᾿ᾊைஹᾌ மιᾠΆ சி ாியᾰᾊῂ ᾺேராᾋᾹ ᾚலΆ 
ெபாிேயாடாᾹᾊᾊῄ ேநாயாளிக῀ மιᾠΆ ெபாிேயாடாᾹᾊᾊῄ மιᾠΆ நீாிழிᾫ 
வைக இரᾶᾌ உ῀ள ேநாயாளிகளிᾹ ரᾷதᾷதி᾿ கᾶடறித᾿. 
 
7. பிᾹᾗல தகவ᾿க῀  
ெபாிேயாடாᾹᾊᾊῄ எᾔΆ ஈᾠ ேநாயானᾐ வாயி᾿ தᾱᾁΆ 
ᾒᾶᾎயிாிகளிᾹ ᾚலΆ உᾶடாகிறᾐ  .இதைன ஈᾌ ெசᾼய நமᾐ உடᾢᾹ ேநாᾼ 
எதிᾺᾗ ெச᾿க῀ ாியᾰᾊῂ ஆᾰசிஜᾹ ᾲெபசீῄ எᾹற ᾚலᾰᾂιறிைன 
உᾶடாᾰᾁகிᾹறன  .இதᾹ ᾚலΆ ஏιபᾌΆ திᾆ பாதிᾺைப ேமலனா᾿ᾊைஹᾌ எᾹற 
ᾚலᾰᾂιறிைன கᾶடறிவதிᾹ ᾚலΆ உᾠதிᾺபᾌᾷதலாΆ  .இᾸத ஆᾰᾭேடᾊῂ 
ῄ᾵ெரῄ  ,மιᾠΆ சி ாியᾰᾊῂ ᾺேராᾋᾹ எᾹᾔΆ ᾗரதΆ ஆகியைவ நீாிழிᾫ ,
ெபாிேயாடாᾹᾊᾊῄ மιᾠΆ இᾞதய ேநாᾼ பாதிᾺᾗகளி᾿ ᾙᾰகிய பᾱகாιᾠகிறᾐ. 
8. ஆராᾼᾲசிைய அறிவிய᾿ ாீதியாக உᾠதிᾺபᾌᾷᾐத᾿  
ெபாிேயாடாᾹᾊᾊῄ மιᾠΆ நீாிழிவிᾹ இரᾶடாΆ வைக ஆகிய இᾞ 
ேநாᾼகᾦΆ ᾊᾹஏ பாதிᾺᾗ மιᾠΆ ஆᾰᾭேடᾊῂ ῄ᾵ெரῄ பாதிᾺைப 
ஏιபᾌᾷதᾰᾂᾊயᾐ . 
9. ெசᾼᾙைற  
 ஆᾼவிைனᾰ ᾁறிᾷத ஓᾺᾗத᾿ வாᾰᾁᾚலΆ ெபιற பிறᾁ ேநாயாளிகளிடΆ 
இᾞᾸᾐ 5 மிᾢ இரᾷதΆ எᾌᾰகᾺப᾵ᾌ ப᾿ மιᾠΆ ஈᾠ பᾁதிகளிᾹ நிைல ᾁறிᾷᾐ 
ேசாதைன ெசᾼᾐ  தனிதனி பᾊவᾱகளி᾿ பதிᾫ ெசᾼயᾺபᾌΆ .  
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 இரᾷதΆ எᾌᾷத அᾹேற அᾸத ரᾷதமானᾐ திᾞவனᾸதᾗரᾷதி᾿ உ῀ள 
ெஜனிᾊகா மரபᾎ ஆᾼவகᾷதிιᾁ அᾔᾺபᾺபᾌΆ.  
 
10. எதி᾽பா᾽ᾰᾁΆ பᾰகவிைளᾫக῀  
ஏᾐமி᾿ைல  
 
11. ஆராᾼᾲசியி᾿ பᾱᾁ ெபᾠபவ᾽கᾦᾰᾁ கிைடᾰᾁΆ நᾹைமக῀  
உᾱகᾦᾰᾁ ேநரᾊ நᾹைமக῀ கிைடᾰகᾺெபறவி᾿ைல எᾹறாᾤΆ 
உᾱகளிடΆ இᾞᾸᾐ எᾌᾰகᾺபᾌΆ ரᾷதΆ மரபᾎ ᾁறிᾷத ஆᾼவிιᾁΆ எதி᾽கால 
கᾶᾌபிᾊᾺபிιᾁΆ பயᾹபᾌΆ. இதி᾿ கᾶடறியᾺபᾌΆ காரணிக῀ 
அதிகாிᾰᾁΆேபாᾐ இᾞதய ேநாᾼக῀ ஏιபட வாᾼᾺᾗக῀ அᾷகΆ எᾹபதா᾿ இᾸத 
காரணிகைள ᾙᾹᾂ᾵ᾊேய கᾶடறிவதிᾹ ᾚலΆ இᾞதய ேநாᾼகைள தᾌᾰகலாΆ. 
12. தᾱகைளᾺ பιறிய விவரᾱக῀ அைனᾷᾐΆ பாᾐகாᾰகᾺபᾌமா? 
உᾱகளிᾹ தகவ᾿க῀ அைனᾷᾐΆ பாᾐகாᾰகᾺபᾌΆ  .இᾸத பᾊவᾷதி᾿ நீᾱக῀ ஒᾺᾗ  
இᾌவதிᾹ ᾚலΆ உᾱக῀ தகவ᾿கைள ᾙதᾹைம ஆᾼவாளேரா அ᾿லᾐ 
வழிகா᾵ᾊேயா ேதைவᾺப᾵டா᾿ எᾌᾷᾐ பா᾽ᾰக ᾙᾊᾜΆ  .இᾸத ஆᾼவிᾹ ᾙᾊᾫக῀ 
வᾞᾱகாலᾷதி᾿ அறிவியல◌் கᾞᾷதரᾱᾁகளிேலா அ᾿லᾐ அறிவிய᾿ 
நாேளᾌகளிேலா உᾱக῀ தனிᾺப᾵ட தகவ᾿க῀ தவி᾽ᾷᾐ பதிᾫ ெசᾼயᾺபடலாΆ . 
13. எதιகாக நாᾹ இᾸத ஆராᾼᾲசிᾰᾁ ேத᾽ᾸெதᾌᾰகᾺᾺப᾵ேடᾹ? 
உᾱகᾦᾰᾁ ெபாிேயாடாᾹᾊᾊῄ மιᾠΆ நீாிழிவிᾹ இரᾶடாΆ வைக ஆகிய 
இᾞ ேநாᾼகᾦΆ அ᾿லᾐ இைவகளி᾿ ஏேதᾔΆ ஒᾹᾠ இᾞᾺபதா᾿ 
ேத᾽ᾸெதᾌᾰகᾺப᾵ᾌ῀ளீ᾽க῀. 
14. இᾸத ஆராᾼᾲசியி᾿ எᾷதைனநப᾽க῀ பᾱᾁெபᾠகிறா᾽க῀? 
  75 நப᾽க῀ பᾱᾁெபᾠகிறா᾽க῀ 
15. இᾸத ஆராᾼᾲசியி᾿ ஏேதᾔΆ தீᾱᾁ ஏιᾺப᾵டா᾿ அᾐ எῂவாᾠ ஈᾌ 
ெசᾼயᾺபᾌΆ ? 
இᾸத ஆராᾼᾲசியி᾿ ஏேதᾔΆ தீᾱᾁ ஏιᾺப᾵டா᾿ அதιகான மᾞᾷᾐவ 
ெசலைவ ᾙதᾹைம ஆᾼவாள᾽ ஏιᾠᾰெகா῀வா᾽ . 
16. இᾸத ஆராᾼᾲசியி᾿ ஏேதᾔΆ தீᾱᾁ ஏιᾺப᾵டா᾿ இைடயி᾿ 
விலகிᾰெகா῀ளலாமா? 
தᾱகᾦᾰᾁ இᾸத ஆராᾼᾲசியி᾿ பᾱᾁ ெபறᾫΆ விலகிᾰெகா῀ளᾫΆ ᾙᾨ 
ᾆதᾸதிரΆ உᾶᾌ  .இதி᾿ இᾞᾸᾐ விலகிᾰெகா῀வதா᾿ உᾱகᾦᾰᾁ எᾸத தீᾱᾁΆ 
ஏιபடாᾐ.  
17. இᾸத ஆராᾼᾲசியி᾿ ஏேதᾔΆ ᾗதிதாக கᾶᾌபிᾊᾰகᾺப᾵டா᾿ எனᾰᾁ 
அறிவிᾰகᾺபᾌமா? 
ஆΆ  .இᾸத ஆராᾼᾲசியி᾿ ஏேதᾔΆ ᾗதிதாக கᾶᾌபிᾊᾰகᾺப᾵டா᾿  
உᾱகᾦᾰᾁ கᾶᾊᾺபாக அறிவிᾰகᾺபᾌΆ.  
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18. எᾷதைன நா᾵க῀ இᾸத ஆராᾼᾲசியி᾿ பᾱᾁ ெபற வர ேவᾶᾌΆ? 
இரᾶᾌ ᾙைற ம᾵ᾌΆ வᾸதா᾿ ேபாᾐΆ. 
 
19. ேமιெகாᾶᾌ நாᾹ ெதாட᾽ᾗ ெகா῀ள எᾹன ெசᾼய ேவᾶᾌΆ ? 
 
 
     
 
 
 
 
 
 
 
 
இடΆ     ᾙதᾹைம ஆராᾼᾲசியாளாிᾹ ைகெயாᾺபΆ 
நா῀ 
 
 
 
 
 
 
ஆᾼைவ பιறிய சᾸேதகᾱகᾦᾰᾁ ெதாட᾽ᾗ ெகா῀ள ேவᾶᾊய 
ᾙகவாி: 
 
டாᾰட᾽. பிளசிᾱ இΆமாᾔேவ᾿ ᾖ 
ᾙᾐநிைல ப᾿ மᾞᾷᾐவ மாணவ᾽ 
ப᾿ மιᾠΆ ஈᾠ ேநாᾼபிாிᾫ 
ᾯ ᾚகாΆபிகா ப᾿ மᾞᾷᾐவᾰ க᾿ᾤாி 
ᾁலேசகரΆ - 629161 
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CONSENT FORM 
PART 2 OF 2 
                PARTICIPANTS CONSENT FORM 
The details of the study have been explained to me in writing and the details have 
been fully explained to me. I confirm that I have understood the study and had the 
opportunity to ask questions. I understand that my participation in the study is 
voluntary and that I am free to withdraw at any time, without giving any reason, 
without the medical care that will normally be provided by the hospital being 
affected. I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). I have been given an 
information sheet giving details of the study. I fully consent to participate in the 
study titled: “EFFECT OF NON SURGICAL PERIODONTAL THERAPY ON 
THE MICRONUCLEI FREQUENCY, SERUM MALONDIALDEHYDE AND 
SERUM HIGH SENSITIVE C – REACTIVE PROTEIN LEVELS IN CHRONIC 
PERIODONTITIS PATIENTS WITH AND WITHOUT WELL CONTROLLED 
TYPE 2 DIABETES MELLITUS”  
Serial no / Reference no:          
Name of the participant:      
Address of the participant: 
Signature / thumb impression of the Parent / Legal guardian 
Witnesses:       
1. 
2. 
Date: 
Place: 
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k½X]{Xw 
`mKw þ 2 
 
 Cu ]T\s¯ ]änbpÅ FÃm Imcy§fpw F\n¡v ]dªv a\Ênem¡n XcnIbpw AXnsâ Hcp 
]IÀ¸v F\n¡p \ÂIpIbpw sNbvXn«p­v.  Cu ]T\w KthjW¯n\mbn DÅXmsW¶pw F\n¡v  CXnÂ 
\n¶v  t\cn«v  Hcp ^ehpw D­mInsÃ¶pw Rm³ a\Ênem¡p¶p.  Cu ]T\¯nsâ  coXnbpw Dt±ihpw 
F\n¡v  a\Ênem¡n X¶n«p­v.  AXp t]mse  F\n¡v kwib§Ä tNmZn¡m³  Ahkc§Ä  e`n¨n«pap­v.  
CXnÂ ]s¦Sp¡m\pw  ]s¦Sp¡mXncn¡m\pw  DÅ AhImiw  F\n¡ps­¶pw  AXpt]mse  ]T\¯nsâ 
GXp L«¯nepw  CXnÂ \n¶v ]n³h§m\pÅ kzmX{´yhpw F\n¡ps­¶v  Rm³ a\Ênem¡p¶p. Cu 
]T\¯nÂ ]s¦Sp¡p¶XpsImt­m, ]s¦Sp¡m¯XpsImt­m Fsâ aäp NnInÕIsf 
_m[n¡p¶XsÃ¶v Rm³  Andbp¶p. “രക്തത്തി  ഉള്ള മൈകര്ോന്യൂക്ളിയ, മലോനാ ഡിഹൈഡ,് എച ്
സ് സി ആ  പി എനന്ിവയുടെ  അളവുക  പ്രമേഹം ഉള്ളവരും  ഇല്ലാതത്വരുമായ പെരിയോഡോന്റിറ്റിസ ്
രോഗികളി : ഒരു ടെസ്റ്റ് ട്യൂബ ് പഠനം” F¶ KthjW¯nÂ ]s¦Sp¡p¶Xn\pw CXnsâ ^e§Ä 
imkv{XteJ\¯nÂ {]kn²oIcn¡p¶Xn\pw F\n¡v k½XamsW¶v Rm³ CXn\mÂ 
Andbn¨psImÅp¶p.  
 
kocnbÂ \¼À / d^d³kv \¼À : 
]s¦Sp¡p¶ Bfnsâ t]cv : 
taÂhnemkw : 
t^m¬ \¼À :  
 
                H¸v / hnceSbmfw 
km£n :   
    
Øew : 
XobXn  
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ஒᾺᾗத᾿ பᾊவΆ 
இரᾶடாΆ பாகΆ 
பᾱேகιபாளாிᾹ ஒᾺᾗத᾿ 
 
இᾸத ஆᾼவிᾹ தகவ᾿க῀ அைனᾷᾐΆ எனᾰᾁ வாᾼ ெமாழியாகᾫΆ எᾨᾷᾐ 
ெமாழியாகᾫΆ ெதாிவிᾰகᾺப᾵டᾐ  .இᾸத ஆᾼவி᾿ நானாக ᾙᾹவᾸᾐ 
பᾱᾁெபᾠகிேறᾹ என அறிவிᾰகிேறᾹ .இதᾹ ᾚலΆ எனᾰᾁ ேநரᾊ நᾹைமக῀ 
இ᾿ைல எனிᾔΆ இᾸத ஆᾼவிᾹ ᾙᾊᾫ மᾞᾷᾐவᾷᾐைறயிᾹ ᾙᾹேனιறᾷதிιᾁ 
பயᾹபᾌΆ எᾹபைத அறிᾸᾐ இதιᾁ சΆமதிᾰகிேறᾹ  .எனᾰᾁ இᾸத ஆᾼைவᾰ 
ᾁறிᾷத விாிவான தகவ᾿க῀ அடᾱகிய பᾊவΆ தரᾺப᾵ᾌ῀ளᾐ .  
நாᾹ “அᾠைவ சிகிᾲைச இ᾿லா ெபாிேயாடாᾶட᾿ சிகிᾲைசயிᾹ 
தாᾰகᾷைத ைமᾰேரா நிᾝᾰளிைய, ஆᾰᾭேடᾊῂ ῄ᾵ெரῄ பாதிᾺைப 
ேமலனா᾿ᾊைஹᾌ மιᾠΆ சி ாியᾰᾊῂ ᾺேராᾋᾹ ᾚலΆ ெபாிேயாடாᾹᾊᾊῄ 
ேநாயாளிக῀ மιᾠΆ ெபாிேயாடாᾹᾊᾊῄ மιᾠΆ நீாிழிᾫ வைக இரᾶᾌ உ῀ள 
ேநாயாளிகளிடᾙΆ கᾶடறித᾿ ” எᾹற இᾸத ஆᾼவி᾿ பᾱேகιக ᾙᾨ மனᾐடᾹ 
சΆமதிᾰகிேறᾹ . 
 
 
ᾁறிᾺᾗ எᾶ 
 
 
ெபய᾽        ைகெயாᾺபΆ /ைகேரைக 
பதிᾫ 
ᾙகவாி 
 
 
ெதாைலேபசி எᾶ   
 
சா᾵சி  1 .  
 
  2 .  
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CASE RECORD FORM 
 “EFFECT OF NON SURGICAL PERIODONTAL THERAPY ON THE MICRONUCLEI 
FREQUENCY, SERUM MALONDIALDEHYDE AND SERUM HIGH SENSITIVE C – 
REACTIVE PROTEIN LEVELS IN CHRONIC PERIODONTITIS PATIENTS WITH AND 
WITHOUT WELL CONTROLLED TYPE II DIABETES MELLITUS” 
Name:  
Address: 
 
 
 
Age  Sex Male Female 
Residence Rural Urban Coastal 
Educational Level: Primary Secondary 
Higher 
Secondary 
Graduate/Pos
t graduate 
Occupational Type: Sedentary Non-sedentary 
Socio-economic status: Low Average High 
Height:  
Weight:  
Abdominal Circumference  
BMI  
Obesity Yes No 
Regular exercise Yes No 
Physical activity Good Average Poor 
Smoking Yes No 
Alcohol Consumption Yes No 
Habit of Chewing Yes No 
Use of Medication/drugs/pills Yes No 
Frequency of brushing   
(per day) 
1 2 >2 
Use of  tooth paste Yes No 
Use of mouthwash Yes No 
Bleeding gum during brushing Yes No 
Sensitive teeth Yes No 
Family H/o gum problem Yes No 
Dental prosthesis Fixed Removable None 
Mental stress Yes No 
H/o Diabetes Yes No 
H/o Hypertension Yes No 
H/o Dyslipidemia Yes No 
H/o CAD Yes No 
Diet Vegetarian Non-Vegetarian 
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INVESTIGATIONS 
 
FBS  
RBS  
HbA1c  
Total Cholesterol  
MDA  
CBMN frequency  
Hs - CRP  
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PERIODONTAL PARAMETERS 
PLAQUE INDEX 
                                                                                                
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
 
                                                                                                
                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
 
Plaque index score: 
GINGIVAL INDEX: 
                                                                                                
                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
 
                                                                                                
                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
 
Gingival Index Score: 
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PROBING POCKET DEPTH 
 
 
GINGIVAL RECESSION/ GINGIVAL ENLARGEMENT 
 
 
CLINICAL ATTACHMENT LEVEL 
 
Signature of Investigator 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                                                                
                                                                                                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                                                                
                                                                                                
18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                                                                
                                                                                                
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
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Group wise clinical parameters obtained. (Pre-Operative data) 
Patient code for Group 1 - A1 - A28 
Patient code for Group 2 - B1 - B27  
Patient code for Group 3 - C1 - C28 
PATIENT CODE AGE PI SCORE GI SCORE MEAN PPD MEAN CAL 
A1 45 1.9 2.1 4.87 4.9 
A2 37 2.1 2.3 4.8 5.02 
A3 39 1.8 1.9 4.28 4.56 
A4 51 1.6 1.8 4.36 4.67 
A5 58 1.38 1.9 4.5 4.76 
A6 41 1.7 2.1 4.3 4.64 
A7 48 1.4 2.3 4.38 4.68 
A8 58 1.6 1.8 4.89 5.2 
A9 54 1.8 2.1 4.65 5.21 
A10 49 1.6 1.7 4.72 5.1 
A11 41 2.1 2.3 4.28 4.5 
A12 40 1.8 2.1 4.87 5.05 
A13 46 1.7 1.6 4.62 4.95 
A14 51 1.5 1.7 4.3 4.5 
A15s 38 1.1 1.2 4.32 4.65 
A16 50 1.4 1.5 4.11 4.2 
A17 38 1.5 1.7 4.28 4.5 
A18 56 1.9 2.1 4.64 5.04 
A19 48 1.8 1.8 4.9 5.3 
A20 46 1.7 2.03 4.3 4.67 
A21 53 1.7 1.8 4.25 4.68 
A22 58 1.8 1.6 4.86 5.2 
A23 54 1.7 1.8 4.82 5.3 
A24 51 1.74 1.87 4.07 4.4 
A25 58 1.31 1.48 3.64 3.96 
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A26 49 1.8 1.87 3.97 4.43 
A27 41 1.42 1.67 5.48 5.7 
A28 58 1.75 1.87 4.5 4.86 
B1 31 1.9 2.4 3.92 4.08 
B2 45 2.2 2.4 3.62 4.17 
B3 43 1.6 1.8 4.06 4.85 
B4 33 1.9 2.1 3.72 4.06 
B5 44 1.3 1.9 3.73 4.82 
B6 38 2.1 2.3 4.11 4.76 
B7 39 1.2 1.4 3.4 3.4 
B8 38 1.6 1.8 3.64 3.82 
B9 31 1.6 1.7 3.9 4.12 
B10 39 2.1 2.3 4.1 4.3 
B11 30 1.9 2.1 3.8 3.8 
B12 33 1.6 1.9 3.43 3.7 
B13 34 1.65 1.8 3.74 3.93 
B14 34 1.43 1.5 3.38 3.63 
B15 31 1.3 1.4 4.2 4.5 
B16 31 1.4 1.4 4.36 4.86 
B17 43 1.5 1.64 4.28 4.51 
B18 44 1.42 1.5 3.84 4.45 
B19 38 1.5 1.5 3.84 4.64 
B20 48 1.4 1.6 4.2 4.67 
B21 31 1.6 1.5 3.9 4.4 
B22 30 1.5 1.5 3.79 4.1 
B23 33 1.5 1.6 3.68 4.2 
B24 34 1.5 1.5 3.75 4.14 
B25 38 1.5 1.3 4.1 4.52 
B26 39 1.5 1.51 3.76 4.8 
B27 45 1.8 1.75 4.2 4.8 
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C1 31 1.2 0.9 2.3 2.3 
C2 35 1.1 1.1 2.1 2.1 
C3 32 1.2 0.8 2.23 2.23 
C4 36 1.6 1.8 2.56 2.56 
C5 36 1.4 1.4 2.3 2.3 
C6 35 1.3 1.3 2.5 2.5 
C7 30 1.1 0.8 2.38 2.38 
C8 30 1.1 0.9 2.4 2.4 
C9 34 1.45 1.77 2.43 2.43 
C10 35 1.3 1.1 2.42 2.42 
C11 34 1.1 0.9 2.1 2.1 
C12 31 1.5 1.6 2.8 2.8 
C13 36 1.72 1.65 2.52 2.52 
C14 32 1.5 1.43 2.5 2.5 
C15 38 1.39 1.35 2.79 2.79 
C16 31 1.25 1.3 2.85 2.85 
C17 31 1.27 1.43 2.65 2.65 
C18 31 1.73 1.44 2.69 2.69 
C19 30 1.36 1.54 2.68 2.68 
C20 36 1.17 1.3 2.6 2.6 
C21 31 1.125 1.32 2.68 2.68 
C22 33 1.4 1.8 2.39 2.39 
C23 30 1.14 1.15 2.57 2.57 
C24 31 1.07 1.14 2.63 2.63 
C25 32 1.46 1.45 2.32 2.32 
C26 31 1.37 1.44 2.55 2.55 
C27 36 1.39 1.45 2.61 2.61 
C28 30 1.37 1.39 2.82 2.82 
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Group wise laboratory parameters obtained. (Pre-Operative data) 
Patient code for Group 1 - A1 - A28 
Patient code for Group 2 - B1 - B27  
Patient code for Group 3 - C1 - C28 
 
PATIENT 
CODE 
RBS Total 
Choles
trol 
Triglyceri
de 
HbA
1C 
hsCRP MDA Mean CBMN 
frequency 
A1 113 230 304 6.12 8.65 3.2 12.26 
A2 122 245 312 6.8 9.5 3.85 13.9 
A3 156 259 320 6.95 9.2 3.41 13.4 
A4 110 219 275 6.12 8.56 3.35 12.6 
A5 175 210 338 6.85 9.45 3.95 13.86 
A6 136 223 295 6.47 9.36 3.69 13.56 
A7 148 258 224 6.56 8.9 3.4 13.03 
A8 158 249 315 5.95 7.59 3.25 13.25 
A9 196 263 313 6.1 8.41 3.9 13.8 
A10 147 258 298 6.11 8.25 3.41 13.48 
A11 126 206 186 6.58 8.95 3.2 12.45 
A12 131 233 195 6.87 8.74 3.25 12.49 
A13 163 287 302 6.21 8.66 3.69 13.59 
A14 150 280 315 5.93 7.39 3.25 12.48 
A15- 115 210 204 6.57 8.91 3.14 12.21 
A16 157 218 285 6.52 8.75 3.59 13.6 
A17 127 240 186 6.3 8.12 3.28 12.58 
A18 144 266 175 6.29 9.12 3.47 13.4 
A19 136 254 185 6.41 8.96 3.74 13.7 
A20 174 270 310 6.89 9.19 3.56 13.45 
A21 186 237 195 6.12 8.12 3.47 13.5 
A22 125 225 296 6.34 8.88 3.69 13.57 
A23 162 238 269 6.45 8.74 3.5 13.5 
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A24 185 230 285 6.88 9.58 3.4 13.8 
A25 146 256 214 6.71 8.66 3.1 12.9 
A26 131 220 176 6.95 9.21 2.9 13.2 
A27 147 236 158 6.66 8.39 2.65 12.58 
A28 139 213 247 6.99 9.35 3.4 13.7 
B1 88 125 85 4.36 6.54 2.59 11.56 
B2 110 136 92 4.88 6.95 2.54 11.97 
B3 86 185 99 5.96 7.24 2.6 12.6 
B4 85 156 108 5.34 7.36 2.6 12.6 
B5 112 191 112 4.55 7.89 3.2 12.16 
B6 96 175 96 5.98 7.64 3.85 12.89 
B7 98 201 88 4.69 7.12 2.96 12.01 
B8 95 186 114 5.15 7.58 3.69 12.63 
B9 103 159 108 4.35 7.06 2.96 12.35 
B10 89 150 112 4.96 6.32 2.15 11.9 
B11 96 129 102 4.78 7.45 2.84 12.25 
B12 85 125 102 4.52 6.87 2.6 11.6 
B13 91 145 124 5.36 7.14 2.63 12.64 
B14 89 204 94 4.4 7.19 2.14 12.3 
B15 96 161 83 4.63 6.23 3.12 11.5 
B16 110 171 112 4.12 6.12 2.74 11.96 
B17 95 185 115 5.71 7.2 3.12 12.5 
B18 100 201 136 5.69 7.14 2.55 12.41 
B19 79 210 148 4.88 6.39 2.1 11.6 
B20 98 182 105 4.17 7.09 2.78 12.01 
B21 101 165 136 5.48 7.31 2.96 12.8 
B22 86 149 112 4.26 6.4 2.5 11.6 
B23 96 180 115 4.85 6.21 2.48 11.7 
B24 89 174 126 4.56 7.28 1.6 12.01 
B25 91 156 157 4.32 6.19 2.91 11.9 
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B26 86 145 114 5.52 7.11 2.4 12.4 
B27 96 175 186 4.3 6.11 3.2 11.3 
C1 63 145 135 3.56 1.25 0.85 10.36 
C2 107 172 115 4.52 1.96 0.86 10.2 
C3 107 186 115 3.63 0.96 1.02 9.33 
C4 105 114 114 4.11 1.47 0.89 10.08 
C5 95 123 120 3.28 1.36 0.89 10.2 
C6 96 142 89 3.75 1.45 0.86 10.7 
C7 75 115 124 3.69 1.55 1.03 10.25 
C8 83 121 105 3.33 1.74 1.14 10.4 
C9 98 128 113 4.15 1.85 0.9 10.64 
C10 95 158 128 3.96 1.36 0.85 10.36 
C11 75 115 93 3.14 0.945 0.96 9.4 
C12 77 163 125 3.3 1.12 0.86 9.8 
C13 95 161 96 3.19 0.95 1.02 9.33 
C14 85 120 105 3.74 0.85 1.12 9.21 
C15 75 179 99 3.51 0.896 1.3 9.6 
C16 78 195 144 3.47 0.86 1.69 9.85 
C17 86 168 118 3.88 0.95 1.5 9.5 
C18 105 176 122 3.56 1.3 1.45 9.63 
C19 95 150 94 3.89 1.66 1.45 10 
C20 75 134 109 3.15 0.94 0.95 9.5 
C21 81 153 124 3.78 0.88 1.23 9.5 
C22 100 186 124 3.45 0.96 1.4 9.14 
C23 94 168 110 3.87 1.49 0.96 10 
C24 94 175 106 3.1 0.89 0.89 9.7 
C25 95 142 115 3.26 0.99 1.63 9.2 
C26 109 136 95 3.17 1.11 1.69 9.56 
C27 83 195 124 3.22 0.85 1.78 9.3 
C28 105 174 102 3.19 1.54 0.89 10.9 
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Group wise clinical parameters obtained. (Post-Operative data) 
Patient code for Group 1 - A1P - A28P (Lost follow-up A4-A6) 
Patient code for Group 2 – B3P - B27P (Lost follow-up B1-B2) 
Patient code for Group 3 – C4P - C28 (Lost follow-up C1-C3) 
PATIENT CODE PI SCORE GI SCORE MEAN PPD MEAN CAL 
A1P 0.5 0.64 2.63 3.01 
A2P 0.42 0.32 2.5 2.7 
A3P 0.23 0.25 2.5 2.78 
A7P 0.67 0.9 3.5 3.61 
A8P 0.4 0.6 2.7 3.1 
A9P 0.42 0.65 2.32 2.65 
A10P 0.32 0.4 2.6 3.1 
A11P 0.5 0.52 2.32 2.45 
A12P 0.32 0.36 2.8 3.2 
A13P 0.4 0.41 2.6 2.9 
A14P 0.2 0.4 2.2 2.9 
A15P 0.23 0.32 2.4 2.65 
A16P 0.31 0.2 2.5 2.63 
A17P 0.1 0.5 2.4 2.98 
A18P 0.23 0.24 2.9 3.1 
A19P 0.4 0.32 2.4 2.85 
A20P 0.64 0.9 3.2 3.75 
A21P 0.32 0.25 2.45 3.1 
A22P 0.23 0.31 2.7 3.1 
A23P 0.23 0.37 2.73 3.1 
A24P 0.43 0.32 2.7 3.2 
A25P 0.23 0.26 2.2 2.47 
A26P 0.23 0.22 2.41 2.78 
A27P 0.27 0.32 2.6 3.1 
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A28P 0.31 0.32 2.7 3.2 
B3P 0.36 0.42 2.41 2.63 
B4P 0.32 0.34 2.72 2.9 
B5P 0.26 0.36 2.25 2.63 
B6P 0.5 0.9 2.46 3.1 
B7P 0.23 0.25 2.45 2.74 
B8P 0.26 0.52 2.65 2.63 
B9P 0.23 0.26 2.72 2.9 
B10P 0.3 0.4 2.7 2.9 
B11P 0.25 0.23 2.12 2.54 
B12P 0.3 0.72 2.46 3.1 
B13P 0.23 0.52 2.72 3.1 
B14P 0.32 0.29 2.62 2.9 
B15P 0.2 0.5 2.3 2.45 
B16P 0.23 0.32 2.5 2.7 
B17P 0.45 0.32 2.63 2.9 
B18P 0.21 0.24 2.12 2.54 
B19P 0.46 0.8 2.21 2.54 
B20P 0.32 0.37 2.63 2.78 
B21P 0.25 0.27 2.38 2.38 
B22P 0.45 0.32 2.21 2.54 
B23P 0.32 0.34 2.45 2.74 
B24P 0.9 0.8 2.67 2.9 
B25P 0.25 0.23 2.3 2.8 
B26P 0.24 0.26 2.7 2.9 
B27P 0.21 0.27 2.6 2.9 
C4P 0.28 0.34 2.6 2.6 
C5P 0.32 0.23 2.31 2.31 
C6P 0.22 0.24 2.51 2.51 
C7P 0.25 0.28 2.72 2.72 
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C8P 0.31 0.37 2.7 2.7 
C9P 0.23 0.26 2.4 2.4 
C10P 0.4 0.32 2.8 2.8 
C11P 0.23 0.25 2.5 2.5 
C12P 0.2 0.28 2.8 2.8 
C13P 0.23 2.24 2.72 2.72 
C14P 0.31 0.28 2.5 2.5 
C15P 0.23 0.24 2.3 2.3 
C16P 0.24 0.26 2.5 2.5 
C17P 0.32 0.31 2.6 2.6 
C18P 0.27 0.31 2.8 2.8 
C19P 0.23 0.28 2.8 2.8 
C20P 0.31 0.29 2.45 2.45 
C21P 0.3 0.29 2.3 2.3 
C22P 0.23 0.25 2.4 2.4 
C23P 0.25 0.25 2.3 2.3 
C24P 0.5 0.5 2.1 2.1 
C25P 0.24 0.31 2.5 2.5 
C26P 0.23 0.27 2.6 2.6 
C27P 0.22 0.23 2.45 2.45 
C28P 0.23 0.24 2.2 2.2 
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Group wise laboratory parameters obtained. (Post-Operative data) 
Patient code for Group 1 - A1P - A28P (Lost follow-up A4-A6) 
Patient code for Group 2 – B3P - B27P (Lost follow-up B1-B2) 
Patient code for Group 3 – C4P - C28 (Lost follow-up C1-C3) 
PATIE
NT 
CODE 
RBS Total 
Cholestro
l 
Triglycerid
e 
HbA1
C 
hsCRP MDA Mean CBMN 
frequency 
A1P 105 205 274 5.96 5.24 2.5 12.15 
A2P 113 208 256 6.35 6.39 1.46 13.12 
A3P 148 194 277 6.55 6.14 2.6 13.01 
A7P 120 210 210 6.12 5.19 2.63 13.01 
A8P 149 229 245 5.56 4.12 1.58 13.1 
A9P 150 241 236 5.74 5.46 2.95 13.12 
A10P 138 245 240 5.85 5.25 2.15 13.27 
A11P 121 189 152 6.17 5.47 2.74 12.33 
A12P 135 238 198 6.32 8.96 3.35 12.52 
A13P 117 201 279 5.89 5.12 2.36 13.13 
A14P 85 198 236 5.24 4.36 1.47 12.2 
A15P 112 208 196 6.32 5.96 2.45 12.05 
A16P 146 212 240 6.12 5.47 2.95 12.49 
A17P 130 245 189 5.89 8.56 3.46 12.6 
A18P 140 245 172 5.74 6.25 2.49 12.06 
A19P 132 236 181 6.12 5.21 2.88 13.2 
A20P 166 156 290 6.21 6.39 2.33 13.38 
A21P 110 210 152 5.89 5.36 2.47 12.96 
A22P 120 210 288 5.94 5.14 2.54 13.13 
A23P 168 240 272 6.13 8.9 3.74 13.64 
A24P 170 215 280 6.29 3.47 2.14 13.2 
A25P 120 180 195 6.33 5.49 2.71 12.46 
A26P 127 215 175 6.48 6.12 1.98 12.8 
A27P 132 126 154 6.22 5.12 1.77 12.12 
Annexure-7 
 
   
 
A28P 130 209 240 6.49 6.47 2.94 13.06 
B3P 81 180 96 5.12 4.8 2.15 12.4 
B4P 114 188 99 4.96 4.1 2.4 12.44 
B5P 101 179 109 4.12 4.36 2.6 12.02 
B6P 97 181 94 5.56 4.25 2.98 12.63 
B7P 101 206 91 4.12 7.41 3.1 12.25 
B8P 90 174 110 4.86 4.55 2.88 12.46 
B9P 93 153 102 4.12 4.36 2.56 12.17 
B10P 85 149 110 4.44 3.26 1.85 11.61 
B11P 91 127 98 4.21 4.12 2.41 12.11 
B12P 84 124 93 4.36 3.33 2.12 11.24 
B13P 90 155 120 5.33 4.78 2.47 12.39 
B14P 70 172 90 4.21 4.18 1.98 12.04 
B15P 88 146 80 4.6 3.45 2.95 11.32 
B16P 97 169 110 4.1 3.17 2.11 11.44 
B17P 85 180 112 5.56 4.52 2.47 12.31 
B18P 98 188 125 5.54 4.16 2.48 12.14 
B19P 76 195 139 4.65 3.16 1.54 11.12 
B20P 105 186 110 4.1 7.25 2.96 12.24 
B21P 92 156 132 5.33 4.32 2.36 12.14 
B22P 100 168 110 4.44 3.22 2.2 11.25 
B23P 91 177 109 4.8 3.14 2.54 11.15 
B24P 84 165 120 4.56 4.55 0.92 11.45 
B25P 88 154 149 4.12 3.18 2.14 11.39 
B26P 84 140 110 5.12 4.12 1.95 12.01 
B27P 93 173 176 4.12 3.78 2.8 11.06 
C4P 98 110 110 4.1 1.33 0.56 10.01 
C5P 94 121 120 3.27 1.29 0.85 9.56 
C6P 91 140 86 3.14 1.42 0.51 10.69 
C7P 78 118 129 3.66 1.59 1.12 10.45 
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C8P 80 118 97 3.13 1.63 1.12 10.32 
C9P 95 121 110 4.15 1.79 0.83 10.12 
C10P 72 144 124 3.97 1.28 0.81 10.24 
C11P 75 110 94 3.13 0.93 0.87 9.12 
C12P 72 156 119 3.4 1.1 0.86 9.32 
C13P 94 150 95 3.18 0.91 0.99 9.31 
C14P 89 122 112 3.77 0.86 1.25 9.54 
C15P 84 169 85 3.5 0.79 1.01 9.47 
C16P 76 188 130 3.44 0.84 1.48 9.41 
C17P 84 162 114 3.86 0.91 1.22 9.46 
C18P 99 170 120 3.51 1.28 1.03 9.51 
C19P 91 145 91 3.88 1.63 1.14 9.48 
C20P 73 120 104 3.15 0.87 0.91 9.43 
C21P 83 158 129 3.79 0.91 1.32 9.67 
C22P 94 174 121 3.46 0.92 1.03 9.09 
C23P 92 158 107 3.85 1.44 0.88 9.87 
C24P 90 170 93 3.11 0.84 0.71 9.5 
C25P 93 133 112 3.29 0.93 1.16 9.19 
C26P 105 118 94 3.5 0.85 1.42 9.42 
C27P 82 184 113 3.21 0.81 1.55 9.29 
C28P 98 170 97 3.17 1.14 0.73 10.45 
 
